SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions August inventions list 08/06

20060193768 - Contrast agent: A contrast agent of formula I: V-L-R (I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linear or branched amino acid-comprising biomodifier or linker moiety, and R is a reporter moiety detectable in in vivo imaging of a human or...

20060193769 - Drug releasing biodegradable fiber for delivery of therapeutics: The present invention relates to fiber compositions comprising gels or hydrogels. The invention further relates to the composition of a gel or hydrogel loaded biodegradable fiber and methods of fabricating such fibers. The present invention further provides tissue engineering and drug-delivery compositions and methods wherein three-dimensional matrices for growing cells...

20060193771 - Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins: CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an...

20060193772 - Drugs for treating cancer: The invention aims to provide a medicament for treating cancer in which a cancer therapeutic effect is synergistically increased using a substance inhibiting activities of insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II). According to the invention, there are provided a medicament for treating cancer which comprises a substance...

20060193770 - Method of determining cytokine dosage for myelosuppressive state: The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective...

20060193775 - Embedder compositions and methods for detecting and killing cells in acidic areas of tumors: Embedder compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes an embedder peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the embedder peptide converts...

20060193773 - Imaging agents: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma....

20060193774 - Transporter compositions and methods for detecting and killing cells in acidic areas of tumors: Improved transporter compositions effective for detecting or killing cells in acidic areas of tumors are described. Each composition includes a transporter peptide which at pH 7.2 and above is poly-anionic and so repels from cells in normal tissues, but at lower pH in hypoxic areas of tumors the transporter peptide...

20060193777 - Method of screening compounds for potential efficacy for the treatment of signs of aging: The present invention features a method of screening a compound for potential efficacy for the treatment of at least one sign of aging on the skin selected from the group consisting of enhancing the elasticity of said skin, enhancing the firmness of said skin, or reducing the appearance of wrinkles...

20060193776 - Screening methods employing zebrafish and the blood brain barrier: Use of fish, in particular zebrafish, in screening for substances with an ophthalmological effect or biological effect on the brain or central nervous system and/or effect on a disease or disorder of the brain or central nervous system. Based on identification and characterisation of the blood brain barrier....

20060193781 - Magnetic resonance imaging of metal concentrations: Provided herein is a method of magnetic resonance imaging (MRI) for in vivo mapping of concentration of a target metal ion in at least one tissue using a contrast agent selectively sensitive for the amount of target metal ion where the contrast agent itself contains a non-hydrogen imaging nucleus. Also...

20060193779 - Dental compositions having anti-stokes up converters and methods of use: A dental composition can include at least one polymerizable resin and at least one anti-stokes up converter. Alternatively, a two-part composition can include at least one dental composition configured for placement onto a person's tooth, and at least one anti-stokes up converter to be combined with the at least one...

20060193780 - Fluorescent membrane intercalating probes: The invention relates to a family of cyanine dyes which fluoresce in the far red and near infra red wavelengths of the spectrum and preferably prossess lipophilic side chains. The dyes of the invention are soluble in commercially available membrane staining vehicles, are useful as probes for rapidly staining lipophilic...

20060193778 - Receptor-mediated uptake of peptides that bind the human transferrin receptor: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other...

20060193782 - Abuse-proofed dosage form: The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, including at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and,...

20060193783 - Low dose corticosteroid composition: The present invention relates to a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent...

20060193785 - Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be...

20060193786 - Pharmaceutical composition for intranasal administration containing a cgrp antagonist: The invention relates to pharmaceutical compositions for nasal application, comprising selected CGRP antagonists which are described in WO 98/11128, as well as a process for the preparation thereof....

20060193784 - Scopolamine sublingual spray for the treatment of motion sickness: This invention relates to a scopolamine spray for sublingual administration, used in the treatment and prevention of motion sickness, as well as the treatment and prevention of similar symptoms, such as nausea and vomiting, caused by conditions other than motion sickness. Also provided are methods of treatment, prevention and inhibition...

20060193788 - Acute treatment of headache with phenothiazine antipsychotics: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic....

20060193787 - Nanoparticle-based drug delivery system: A drug delivery system based on at least one type of nanoparticle. In particular, a nanoparticle-based drug delivery system including at least one first drug, at least one second drug and at least one type of nanoparticle....

20060193789 - Film forming foamable composition: A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and...

20060193790 - Promoting whole body health: The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of a host-response modulating agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in mediating host reaction to the presence of periodontal pathogens...

20060193791 - Antiplaque oral care compositions: e

20060193792 - Use of an oral composition: Liquid dentifrice compositions are provided which give improved cleaning performance and flavour display when used in the small amounts that can be dispensed onto a typical electric toothbrush head. The liquid dentifrice has a viscosity of less than about 500 Pa·s at 0.1 s−1 at 25° C. Representative compositions include...

20060193793 - Apparatus and method for whitening teeth: Disclosed herein is a pair of dry type patches for teeth whitening, having a patch for upper teeth and a patch for lower teeth, in which the patch for upper teeth has a shape different from the patch for lower teeth, and each patch has a controlled width and shape...

20060193794 - Patches for teeth whitening: The present invention relates to a dry type tooth-whitening patch comprising peroxide as a tooth whitening agent. In particular, disclosed is a dry type tooth-whitening patch in which peroxide is contained, as a teeth whitening agent, in a matrix type adhesive layer. The adhesive layer includes, as a base polymer...

20060193795 - Appetite suppressant mouth spray: An appetite suppressant mouth spray formulation which simultaneously suppresses the user's appetite while promoting intraoral health. The mouth spray composition includes mouth spray base ingredients; and a plurality of appetite suppressant and appetite depressant herbs. The mouth spray base ingredients include a combination of Water; Glycerin; Xylitol; Propylene Glycol; Sodium...

20060193798 - Aqueous polymer dispersion: An aqueous polymer dispersion prepared by free-radical polymerization of vinyl acetate in the presence of at least one ionic emulsifier, at least one free-radical initiator and at least one protective colloid, wherein the polymerization is carried out in the presence of a polymerization regulator and wherein the ratio by weight...

20060193797 - Chroman derivatives as lipoxygenase inhibitors: wherein X and R1 to R10 are as described in the specification, and where either R5 is OH, —NRdORa or —NRd—NRbRc, or R7 is —NRdORa or —NRd—NRbRc, or C═R7R8 is C═NORa or C═N—NRbRc, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They...

20060193796 - Method for refining ultraviolet absorbent, ultraviolet absorbent and cosmetic material: The process for purifying an ultraviolet absorber of the present invention is characterized by including an adsorbent treatment step of bringing the ultraviolet absorber into contact with an absorbent. According to the process, an ultraviolet absorber having a reduced odor, an improved hue and less skin irritation can be obtained....

20060193799 - Method of making perfluorocarbon emulsions with non-fluorinated surfactants: The present invention provides a method of making a FC emulsion. The method comprises mixing an FC immiscible hydrophilic liquid and a solid emulsifying agent by agitation at a temperature elevated above the phase transition temperature of the emulsifying agent and below the boiling temperature of the FC immiscible hydrophilic...

20060193801 - Solid cosmetic composition textured with an organic copolymer: The present invention relates to a solid cosmetic composition wherein it comprises a liquid fatty phase textured with an effective amount of at least one organic copolymer and in that it has a hardness ranging from 10 to 250 g and an elasticity of greater than 80%....

20060193800 - Variable tint cosmetics: The disclosed systems and methods for delivery of variable tint pigment materials in cosmetic concealer/foundation products generally include anhydrous carrier particles adapted to carry pigment. The pigmentation carrier particles may be optionally admixed with anhydrous (optionally tinted) base formulation material that is suitably adapted to suspend and/or separate the pigmentation...

20060193802 - Aldehyde and alcohol compositions derived from seed oils: An aldehyde composition derived by hydroformylation of a transesterified seed oil and containing a mixture of formyl-substituted fatty acids or fatty acid esters having the following composition by weight: greater than about 10 to less than about 95 percent monoformyl, greater than about 1 to less than about 65 percent...

20060193804 - Haircare use of cyclic amine derivatives: m represents an integer ranging from 0 to 5; and n represents an integer ranging from 0 to 5. or a salt or isomer thereof, leaving the said composition in contact with the keratin fibers and/or the skin from which the fibers emerge, and optionally rinsing the keratin fibers and/or...

20060193803 - Polymer particle dispersions, cosmetic compositions comprising at least one polymer particle dispersion, and cosmetic process using same: Disclosed herein is a dispersion of polymer particles in a liquid carbon-based medium, wherein said polymer is chosen from at least one block copolymer comprising at least one first block that is soluble in said liquid carbon-based medium and at least one second block that is insoluble in said liquid...

20060193805 - Method of preparing emulsions containing elastomeric silanes and siloxanes having quaternary ammonium groups: Oil-in-water (O/W) and water-in-oil (W/O) emulsions and microemulsions containing elastomeric silanes or siloxanes preferably having quaternary ammonium groups are generally made by reacting organic quaternary ammonium compounds having epoxide groups or halohydrin groups, with silanes or siloxanes having amino groups. The reaction is carried out in an aqueous polar phase...

20060193806 - Skin-pampering cream lotion: The cosmetic composition of the invention has a dynamic viscosity/shear stress flow curve with a maximum of up to 10000 Pa·s at the 5-50 Pa region and a shoulder at shear stress 30-110 Pa. The flow curve is determined at 25° C. on a Rheometric Scientific device having a parallel...

20060193817 - Hair or skin conditioning compositions comprising hydrophobically modified amido silicone copolyol: Disclosed are hair or skin conditioning compositions comprising by weight: (a) from about 0.1% to about 10% of a thickening polymer system; (b) from about 0.1% to about 8.0% of a surfactant system selected from the group consisting of cationic surfactant, nonionic surfactant, and mixtures thereof; (c) from about 0.1%...

20060193807 - Charging composition for coating keratin fibers comprising an aprotic wax: The present disclosure relates to a composition for coating keratin fibers, comprising, in a cosmetically acceptable continuous aqueous medium, at least one aprotic wax in an amount of greater than 25% by weight relative to the total weight of the composition, said composition having a dry extract of greater than...

20060193808 - Composition for coating keratin fibers, comprising a fatty alcohol wax and a cellulose-based polymer: The present disclosure relates to a composition for coating keratin fibers, comprising, in a cosmetically acceptable aqueous medium, at least one fatty alcohol wax, and at least one cellulose-based polymer. The present disclosure further relates to the use of such a composition to obtain charging makeup for keratin fibers....

20060193809 - Skin care compositions containing a sugar amine cross reference to related application: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060193810 - Water-in-oil type micro-emulsion: A water-oil type micro-emulsion having high safety to a living body by decreasing the amount of a surfactant to be used or not using the surfactant, and at a high ratio of aqueous phase capable of dissolving effective ingredients, the water-in-oil type micro-emulsion comprising polyvinyl pyrrolidone and one or more...

20060193811 - Composition serving as a carrier for delivery of active ingredients in cosmetic and dermatological applications: The present invention is for a carrier comprising an oil/water emulsion for delivery of active ingredient in a medium of cream or lotion for skin cosmetic and/or dermatological care....

20060193812 - Controlled delivery system for fragrance comprising a (meth)acrylate/hydroxy (meth) acrylate copolymer: A perfuming composition for application to the skin by means of a roll-on, pump-spray, squeeze bottle or aerosol spray type device. The composition includes a perfuming base and, optionally, a deodorant or antiperspirant base, with at least one of the bases being combined with a film-forming substrate and an emulsifier...

20060193813 - Nanoemulsion containing a hydroxylated urea compound: The invention relates to an oil-in-water nanoemulsion having an oily phase dispersed in an aqueous phase, the oil globules of which have a number-average size of less than 100 nm, containing: (i) at least one amphiphilic lipid comprising at least one nonionic amphiphilic lipid, and optionally at least one ionic...

20060193815 - Compositions containing amines and use thereof: e

20060193814 - Compositions for the treatment of signs of aging:

20060193816 - Methods and compositions for biocidal treatments: The present invention provides a composition having disinfectancy & residual antimicrobial activity, where the antimicrobial composition comprises an organosilane quaternary compound and a quaternary ammonium compound and other formulations. Also provided are methods of disinfecting an article or providing an antimicrobial coating to an article using the same....

20060193818 - Compositions containing amines and use thereof: e

20060193819 - Topical cosmetic composition with skin rejuvenation benefits: There are provided topical cosmetic compositions for improving the aesthetic appearance of skin and remediating the effects of aging, and methods of use thereof. One composition is a blend of neem seed cell broth and one or more additional botanical ingredients. Another composition has pomegranate fruit extract and, optionally, one...

20060193820 - Immunostimulating polyphosphazene compounds: Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed....

20060193822 - Antiseptic spermicidal composition and means for its application: This invention provides a spermicidally and virucidally effective, vaginally applicable formulation, having the following approximate composition of essential ingredients: at least one benzalkonium chloride, in an amount from 0.05 to 0-0.2%; at least one spermicide selected from the group consisting of nonoxynols in an amount of from 0.05-12%, octoxynol-9 in...

20060193821 - Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of...

20060193823 - Hydrolytically degradable carbamate derivatives of poly (ethylene glycol): Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be...

20060193824 - Methods for the treatment of infectious and inflammatory airway diseases: Methods for the treatment of inflammatory and infectious airway diseases are disclosed....

20060193826 - Methods to mobilize progenitor/stem cells: wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain,...

20060193827 - Methods using tcf -ii: The present invention provides an agent for preventing and/or treating cachexia comprising TCF-II as an effective ingredient. An agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the...

20060193825 - Pharmaceutical formulations for sustained drug delivery: The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides....

20060193828 - Expression enhancer for hm1.24 antigen: An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-α or interferon-γ, or IRF-2 protein as an active ingredient. Interferon-α or interferon-γ is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen....

20060193829 - Binding molecules for human factor viii and factor viii-like proteins: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of...

20060193833 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such...

20060193830 - Raav vector compositions and methods for the treatment of choroidal neovascularization: Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular,...

20060193831 - Use of pleiotrophin to promote neurogeneration: The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and restoring the nervous system, in patients suffering from, or at risk for, neurodegenerative disorders....

20060193832 - Use of the sodium iodine symporter to effect uptake of iodine: The present invention relates to the use of gene therapy to introduce an iodine symporter into cell to increase iodine uptake therein. This approach has particular utility in the treatment of cancers that incapable of removing iodine. In addition, strategies are provided for reducing the export of sodium from cells...

20060193841 - Method for the treatment of parkinson's disease: A method of treating Parkinson's Disease in patients exhibiting increasing resistance to the administration of L-dopa due to loss of aromatic L-amino acid decarboxylic activity in striatal neurons comprises transfection of the caudate and/or putamen regions with a viral vector encoding AADC. The vector preferably has a promoter system provided...

20060193840 - Perivascular mesenchymal precursor cell induced blood vessel formation: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1...

20060193834 - Antiprotozal composition: A composition, and method of use, for controlling, reducing or preventing the growth of protozoal bacteria in the ruman of a rumiant comprising cell bodies of a facultative anaerobe selected from the group consisting of Corynebacterium cell bodies and Brevibacterium cell bodies or a mixture of Corynebacterium cell bodies and...

20060193842 - Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life: Disclosed is a formulation for preserving the life of probiotic bacteria during passage through the stomach, while permitting their release in the intestine, and which has a low water activity and correspondingly long shelf life. These formulations are designed to retain potency up to the product expiration date. The formulation...

20060193837 - Method and composition for repairing epithelial and other cells and tissue: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating a disease or condition or repairing tissue of skin, mouth or ear with the compositions....

20060193836 - Method and composition for repairing heart tissue: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating heart disease or repairing heart tissue with the compositions....

20060193838 - Method and composition for treating diabetes: The present invention is directed to the TVEMF-expansion of mammalian blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions....

20060193839 - Method of providing readily available cellular material derived from peripheral blood, and a composition thereof: The present invention is directed to the TVEMF-expansion of mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions....

20060193835 - Treatment of congestive heart failure: A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patient's blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering...

20060193843 - Thermostable enzyme compositions: The present invention relates to a composition comprising at least two thermostable enzymes selected from the group consisting of endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, and alpha-galactosidase. The thermostable enzymes have a melting temperature, Tm, of at least 70° C. Preferred compositions comprise a xylanase of glycoside hydrolase family...

20060193844 - Methods for enzyme inhibition: Improved regimens for administering proteasome inhibitors are described, wherein proteasome inhibition is more sustained relative to certain current regimens which permit substantial recovery of proteasome activity between doses of inhibitor....

20060193845 - Combination therapy for controlled carbohydrate digestion: Carbohydrate usage in the gastro-intestinal tract of a subject can be modulated by administering, to a subject, a first agent that inhibits carbohydrate degradation in combination with a second agent that decreases formation or severity of intestinal gas....

20060193846 - Carrier with solid fibrinogen and solid thrombin: The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75...

20060193847 - Peptides for inhibiting retroviruses: Peptides derived from shark immunoglobulin preparations are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. The peptide preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The peptides also inhibit growth of tumor cells, especially sarcomas and leukemias....

20060193850 - Anti a beta antibody formulation: The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product...

20060193849 - Biological materials and uses thereof: A modified antibody molecule which selectively binds to a specific target, the antibody molecule being modified at at least one amino acid residue that determines antigen binding selectivity and/or affinity, characterised in that the modified antibody molecule exhibits a greater stability than an unmodified parent antibody molecule which selectively binds...

20060193851 - Human anti-factor ix/ixa antibodies: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting...

20060193848 - Mammalian tumor susceptibility genes and their uses: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is...

20060193852 - Novel cd19xcd3 specific polypeptides and uses thereof: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said...

20060193853 - Combinations of growth-and hormone-regulating factors for the treatment of neoplasia: The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or...

20060193854 - Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies....

20060193856 - Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such...

20060193858 - Cloning and expression of human slap-2: a novel sh2/ sh3 domain-containing human slap homologue having immune cell-specific expression: The present invention describes a newly discovered full-length polynucleotide encoding an SH2/SH3 domain-containing adapter protein, called hSLAP-2, cloned, isolated and identified. Also described are the hSLAP-2 polypeptide sequence, expression vectors, host cells, agonists, antagonists, anti-sense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Methods for...

20060193855 - Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective...

20060193857 - Modulation of fc gamma receptors for optimizing immunotherapy: The present invention relates to methods for modulating the maturation of dendritic cells. In particular, the invention provides methods for (a) promoting the maturation of dendritic cells thereby producing mature dendritic cells, and (b) preventing the maturation of dendritic cells thereby preventing maturation and producing tolerogenic dendritic cells. The present...

20060193859 - Methods of treatment using antibodies to neutrokine-alpha: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV...

20060193860 - Treatment of schizophrenia: The invention includes methods of treating schizophrenia in a patient where the method includes administration of antibodies to TNF-alpha and interferon-gamma to the patient. The invention further includes methods of treating schizophrenia in a patient where the method comprises administration of an antibody to TNF-alpha....

20060193861 - Tumor necrosis factor receptors 6 alpha & 6 beta: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides and antibodies that bind TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for...

20060193862 - Vascular endothelial cell growth factor antagonists: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterzied by undesirable or excessive neovascularization....

20060193865 - Camptothecin-binding moiety conjugates: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates....

20060193863 - Compositions and methods for diagnosing and treating prostate cancer: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject....

20060193864 - Conversion of apoptotic proteins: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing apoptosis are described, together with methods for identifying molecules that induce apoptosis through interaction with...

20060193866 - H pylori antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from H. pylori, methods for isolating such antigens and specific uses thereof....

20060193867 - Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith: The present invention relates to molecules that are capable of killing cells. The molecules comprise a targeting agent and a channel-forming moiety. The molecules may be polypeptides. The present invention also relates to polynucleotide sequences encoding the polypeptides of the invention. In a preferred embodiment, the channel-forming moiety comprises a...

20060193868 - Functionalized nanotubes: Graphitic nanotubes, which includes tubular fullerenes (commonly called “buckytubes”) and fibrils, which are functionalized by chemical substitution or by adsorption of functional moieties. More specifically the invention relates to graphitic nanotubes which are uniformly or non-uniformly substituted with chemical moieties or upon which certain cyclic compounds are adsorbed and to...

20060193870 - Compositions and methods for the therapy and diagnosis of colon cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20060193869 - Methods and compositions for induction or promotion of immune tolerance: The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates....

20060193871 - Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia: Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging...

20060193872 - Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers: Recombinant VSV viral particles and the use thereof as vaccines for immunization are described....

20060193873 - Functionallly reconstituted viral membranes containing adjuvant: The present invention relates to vaccines directed against antigens such as membrane proteins from pathogens or tumor cells. The invention further relates to methods of forming reconstituted viral membranes, with membrane fusion activity, which are lipid bilayer membranes preferably containing natural lipids of a virus, a viral fusion protein, one...

20060193874 - Vaccines for proliferative ileitis and methods of making and using the same: A proliferative ileitis vaccine comprising tissue culture grown Lawsonia intracellularis and methods of making said vaccines. Proliferative ileitis vaccines described include those containing whole L. intracellularis, extracts of L. intracellularis, protective immunogenic subunits of L. intracellularis, recombinant immunogens of L. intracellularis and naked DNA of L. intracellularis. The vaccines of...

20060193876 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and...

20060193875 - Method of treating human-immunodeficiency virus (hiv) disease infection: Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs....

20060193877 - Compositions and methods of making sustained release liquid formulations: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the...

20060193878 - Method of preparing gas delivering perfluorocarbon emulsions with non-fluorinated surfactants: The present invention provides a method of making a FC emulsion. The method comprises mixing an FC immiscible hydrophilic liquid and a solid emulsifying agent by agitation at a temperature elevated above the phase transition temperature of the emulsifying agent and below the boiling temperature of the FC immiscible hydrophilic...

20060193879 - Topical formulations comprising ceramic hydroxyapatite particles: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing...

20060193880 - Method and compositions for attracting mosquitoes employing (r)-(+)-isomers of 1-alkyn-3-ols: t

20060193881 - Method and compositions for attracting mosquitoes employing (r)-(-) isomers of 1-alken-3-ols:

20060193882 - Particles containing agricultural active ingredients: One or more agricultural active ingredients (such as fungicides or insecticides) are entrapped in polymeric matrixes to form particles having a diameter in the range from about 0.2 to about 200 microns. The particles are applied to soil, to seeds, or to plants and release the active ingredient(s) at a...

20060193883 - Pesticidal treatment materials: The short term effectiveness of pesticidal articles, for example pesticide impregnated textile covers for use in combating dust mite infestation, is improved by the additional presence of a quick release pesticide thereon, e.g. a wettable powder formulation of the same pesticide as used for impregnation. The invention is of particular...

20060193885 - Implantable biomaterial and a method of producing same: The present invention relates to an implantable biomaterial and methods of producing same. In particular, the present invention relates to a method for producing an implantable biomaterial comprising (a) exposing a biomaterial to an alcohol-containing solution for at least 24 hours....

20060193884 - Novel biomaterial drug delivery and surface modification compositions: Compositions are provided which include a polymer made at least in part from a polyoxyalkylene copolymer, such as a poloxamer. The polymer may be combined with a second component to form a blend or emulsion. The resulting composition may be utilized to form medical devices, drug delivery devices, or coatings...

20060193887 - Medical devices having nanoporous bonding layers: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193886 - Medical devices with nanoporous layers and topcoats: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193890 - Method for loading nanoporous layers with therapeutic agent: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193888 - Methods for using medical devices having nanoporous layers: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193889 - Nanoporous layers using thermal dealloying: The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices having at least one porous layer, and methods for making such devices, and loading such devices with therapeutic agents. A mixture or alloy is...

20060193893 - Medical devices: The invention relates to medical devices, compositions and methods useful for administrating or delivering a cephalotaxine to a host. The cephalotaxines are useful in treating or preventing an angiogenic condition or disease. The invention provides for medical devices including coatings containing a matrix and a cephtalotaxine to treat an angiogenic...

20060193891 - Medical devices and therapeutic delivery devices composed of bioabsorbable polymers produced at room temperature, method of making the devices, and a system for making the devices: A method is provided of making a bioabsorbable appliance that includes selecting a first bioabsorbable polymer having a first glass transition temperature above about room temperature and selecting a second bioabsorbable polymer having a second glass transition temperature below about room temperature. The method also includes combining the first and...

20060193892 - Polymer biodegradable medical device: A medical device that is at least partially formed of a biodegradable polymer. The medical device can be at least partially formed by MEMS technology. The medical device can include one or more micro-structures that are also formed by MEMS technology. The medical device can include one or more biological...

20060193894 - Methods for providing biomedical devices with hydrophilic antimicrobial coatings: The invention provides a process for producing devices with stable surface coatings, which coatings are one or both of hydrophilic and antimicrobial....

20060193895 - Additive for food and beverage, pharmaceutical composition, glut4 translocator, and method for translocating glut4: e

20060193896 - Process for manufacturing a delivery system for active components as part of an edible composition: A method of manufacturing a delivery system of at least one active component encapsulated in an encapsulating material, which is useful, for example, for providing delayed and/or controlled release of the active is described....

20060193897 - Enzyme feed additive and animal feed including it: The use is provided of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative...

20060193898 - Line up of wipes products incorporating targeted sensory elements: Line ups of wipes products are disclosed. In particular baby wet wipe line ups having targeted sensory elements are disclosed. The line ups may have targeted scent elements, targeted visual elements, targeted tactile elements and targeted auditory elements. The sensory elements may be provided in combination to reinforce each other...

20060193899 - Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels: Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs....

20060193901 - Mixture for transdermal delivery of low and high molecular weight componds: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed....

20060193900 - Pressure sensitive adhesive and patch: The present invention is a pressure sensitive adhesive comprising: an ingredient (A) which is a copolymer of a carboxyl group-containing monomer and (meth)acrylic ester; and an ingredient (B) which is a copolymer of a pyrrolidone group-containing monomer and (meth)acrylic ester, wherein the ingredient (A) is crosslinked by at least one...

20060193905 - Direct cellular energy delivery system: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a...

20060193903 - Glycoside-containing liposome: A drug product which can maximize the effect of a cholestanol glycoside useful as an anticancer agent. The present invention provides a liposomal composition containing a glycoside exhibiting antitumor activity, a phospholipid, and a positive-charge-providing substance; the glycoside being composed of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- as a sugar...

20060193904 - Liposome loading with metal ions: This invention relates to encapsulation of drugs and other agents into liposomes....

20060193902 - Pharmaceutical compositions containing active agents having a lactone group and transition metal ions: Compositions and methods for stabilizing an active agent containing one or more actone rings. The compositions, including pharmaceutical compositions, ensure that the lactone ring of the active agent is stabilized in the active, ring-closed form due to the inclusion of a transition metal ion....

20060193906 - Sugar-modified liposome and products comprising the liposome: The present invention provides a sugar-modified liposome having a sugar chain bonded to its membrane surface, preferably through a linker protein, and having excellent absorption qualities, particularly in the intestine. The molecular structure and quantity of the sugar chain is selectively varied to allow the liposome to be delivered in...

20060193907 - Ngna compositions and methods of use: The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided....

20060193909 - Breath freshening pressed tablets and methods of making and using same: A confectionery product comprises a pressed tablet made from a compressible composition and having at least one abrasive surface suitable for cleaning the surface of a human tongue in an oral cavity. Typically the product has a first side and a second side generally opposite to the first side; the...

20060193908 - Extended release formulations of poorly soluble antibiotics: An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release...

20060193910 - Tablets with improved drug substance dispersibility: The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid; b) preparing...

20060193913 - 5-(4-(2-n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl) thiazolidine-2,4-dione and pharmaceutical compositions comprising the same: A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (‘Compound (I)’), or a pharmaceutically acceptable form thereof, in particulate form wherein the median value of the volume mean diameter of the particles is within the range 500 nm to 5 micrometres and medicinal uses thereof....

20060193912 - Controlled release o-desmethylvenlafaxine formulations: In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of O-desmethylvenlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL...

20060193911 - Controlled release venlafaxine formulations: In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of...

20060193914 - Crush resistant delayed-release dosage forms: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance...

20060193915 - Compression coated tablets: A pharmaceutical composition for oral administration comprising a compression coated solid dosage form of a bitter or unpleasant tasting pharmaceutically active agent. Included are compression coated oral dosage forms of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The compression coated solid dosage forms are of...

20060193916 - Formulations of peptides for periodontal and dental treatments: Methods to treat the defects in skeletal tissues characterized by protecting the marrow cells adjacent to the defects from apoptotic and/or necrotic cell death are disclosed. The methods provide additional benefits which are to reduce inflammation and irritation in the marrow tissues and assist promoting new skeletal tissue formation to...

20060193917 - Radiosensitizer formulations and methods for use: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents...

20060193918 - Solvent/polymer solutions as suspension vehicles: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group...

20060193919 - Complex of drug-carbon nanohorn and a process for producing the complex: The present invention provides a carbon nanohorn complex that is excellent in characteristics of adsorption or inclusion of drugs and release, in particular, a sustained release of drugs as a novel drug carrier in drug delivery systems, as well as a process for producing the complex. The complex of drug...

20060193921 - Hydrophilic beads for use in topical formulations: A composition and method for producing hydrophilic beads for use in topical formulations is described as generally including gellan gum, salts of divalent cations and water. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of hydrophilic beads to achieve...

20060193920 - Nanoparticulate compositions of mitogen-activated protein (map) kinase inhibitors: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions....

20060193922 - Compositions and methods for the treatment of acne: This invention relates to compositions for the treatment of acne. In a preferred embodiment, the composition comprises adrenal extract and bupleurum root. In another preferred embodiment, the composition further includes licorice root. In another preferred embodiment, the invention also includes at least one vitamin B5 component, a magnesium component, a...

20060193923 - Compositions and methods for increasing muscle mass and strength, improving athletic performance, and/or reducing body fat mass leading to weight loss: Methods and compositions for the inhibition of human aromatase enzyme are presented for the purposes of increasing or activating the total levels of testosterone, free testosterone, and/or luteinizing hormone levels, while decreasing the levels of estrogen and estradiol. The increase in testosterone levels, combined with a proper exercise and diet...

20060193924 - Antimicrobial combination therapy: This invention provides methods and pharmaceutical compositions for treating a subject having a condition associated with an antibiotic resistant bacterial infection. The invention includes administering to a subject a therapeutically effective combination of an antibiotic and a toxic compound (e.g., a nucleic acid damaging agent, an alkylating agent, or a...

20060193925 - Side effect-relieving agents and/or hypoglycemic effect enhancers for thiazolidine compounds: The present invention relates to a side effect-relieving agent for thiazolidine compounds which comprises a crude drug mixture as an active ingredient comprising Ephedrae Herba, Glycyrrhizae Radix and Gypsum Fibrosum each of which is in a form of ground powders, extracts or mixtures of powders and extracts; and a hypoglycemic...

20060193926 - Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and...

20060193927 - Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions: This invention relates to combinations of vasoactive substances which are useful in the treatment of sexual dysfunctions associated with poor local blood supply and/or insufficient lubrication. The active compounds are selected from a:—esculoside or visnadine;—forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;—esters...

20060193929 - Method for treating or preventing symptoms associated with menopause: The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, and a method for treating or preventing a disease, disorder or symptom associated with menopause. The present invention uses a composition comprising as an active ingredient an extract from Cynanchum...

20060193928 - Novel herbal compositions and process for preparation thereof: A process for obtaining various useful extracts from at least one herb includes the steps of extracting lypophilic ingredients through a supercritical CO2 extraction process to obtain a first extract; subjecting the residue thereof to a second supercritical CO2 and alcohol solvent process to obtain slightly polar compounds which define...

20060193930 - Process for the preparation of protein hydrolysate from legumes: The present invention provides a process for the preparation of protein hydrolysate from soy flour, which comprises preparing aqueous slurry of defatted soy flour having 6-12% w/v of solid content, hydrolyzing the said slurry using fungal protease at pH 7-8 and temperature 43±5° C. to get 20-40% degree of hydrolysis...

20060193932 - Morinda citrifolia enhanced colon cancer cell growth inhibitor: The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise...

20060193931 - Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof: The present invention provides a nutritional composition and a pharmaceutical composition to be used for humans or animals comprising as active compound the oleuropein compound or one derivative thereof....

20060193933 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops....

20060188438 - Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a...

20060188437 - Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery: The present invention provides a tumor-homing peptide that can target cancer and or tumor tissues. The peptide is uptaken by certain specific cancer cell types. The invention describes methods to achieve targeted delivery of anticancer drugs conjugated to this peptide for anticancer therapy. The invention also describes methods for using...

20060188440 - Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer: Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided....

20060188439 - Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer...

20060188441 - Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors: Methods for labeling synthesis of radiolabeled gallium complex by microwave activation are provided. The resultant gallium-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). A method for imaging EGFR overexpression in tumors using PET is also provided....

20060188442 - X-ray guided drug delivery: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations...

20060188443 - Diagnostic composition for diabetes type-2 and impaired glucose tolerance, and methods of use: A solid oral diagnostic test meal is provided that contains a polysaccharide, wherein the oral diagnostic test meal provides a medically controlled quantity of glycemic carbohydrate after being ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose...

20060188444 - Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method: s

20060188445 - Assay for compounds that protect against sensory hair cell death and compounds identified by same: The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects....

20060188446 - T-cell epitope peptides: The T-cell epitope site on a Japanese cypress (hinoki) pollen allergen molecule has been identified by stimulating a T-cell line established from a patient suffering from Japanese cypress pollen allergy with an overlap peptide covering the primary structure of the Japanese cypress pollen allergen. The peptide is useful in peptide-based...

20060188447 - Process for the production of an abuse-proofed dosage form: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N,...

20060188448 - Theraputic skin treatment method: A method of using a novel candle apparatus at least includes: candle housing; candle fuel deposited in the candle housing, the candle fuel at least including non-toxic solidified therapeutic skin substance; and a candle fuel liquefier; wherein the candle fuel is adapted to, upon application of the fuel liquefier, liquefy...

20060188450 - System and method for suppressing a cough: A system and method for suppressing coughs, congestion and related symptoms is provided. The composition sprayed into the oral cavity may contain a cough suppressant and other ingredients such as decongestants, flavorings, sweeteners, stablizers, and/or preservatives. The composition is sprayed into the oral cavity utilizing a spray pattern having a...

20060188449 - Topical aerosol foams: A stable topical aerosol foam is provided. The foam-forming formulation includes a HFA propellant and an active agent in an emulsion. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent may be present in either phase or dispersed in the emulsion. The oil phase...

20060188451 - Aerogel based pharmaceutical formulations: Drugs in the form of very fine highly porous aerogel particles are delivered to a patient via inhalation. The aerogel particles are either an aerogelized form of a pharmaceutical or deposited upon aerogel particles produced from a non-inorganic oxide carrier matrix material, e.g. a sugar or carbohydrate. The aerogel particles...

20060188454 - Oral compositions and use thereof: The invention comprises the use of oral compositions of defined rheological characteristics in oral treatment systems, especially a hand-held electric toothbrush, comprising a reservoir and means for pumping the oral composition from the reservoir to an applicator such as a toothbrush head. Pumpable oral compositions having good stand-up on a...

20060188452 - Treatment composition: The invention relates to a dental treatment composition comprising a particulate erasing agent, the particles of the erasing agent being dimensioned to roll along a surface. The particles have an average maximum diameter of between 30 and 1000 microns and consist of a precipitate of calcium carbonate. As the particles...

20060188453 - Use of substitute 2,4-bis (alkylamino)pyrimidines: The use of 2,4—bis(alkylamino)pyrimidines of formula (1) R1 is C1-C12alkyl or C6-C10laryl; R2 is hydrogen or C1-C12alkyl; or R1 and R2 together form a radical of formula (1a) R′ and R″ are each independently of the other hydrogen, C1-C6alkyl or C1-C6alkoxy, R3 and R5 are each independently of the other...

20060188457 - Bodywashes containing additives: The invention encompasses bodywashes containing an additive. The additive may contain a sunscreen. The additive may contain 2, 3, or more than three sunscreens. Optionally, one or more of the sunscreens may be encapsulated. The invention further encompasses methods of making and using bodywashes containing an additive, e.g., an additive...

20060188455 - Siloxanes containing guanidino groups and use thereof for cosmetic formulations: The invention relates to polysiloxanes containing guanidino groups for which the guanidino groups can be combined arbitrarily with other functional groups on the polysiloxane backbone according to the general formula (I)...

20060188458 - Sunscreen compositions and methods of use: The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are...

20060188456 - Uv-light-absorbing quaternary polysiloxanes: The invention relates to UV-light-absorbing quaternary polysiloxanes in which quaternary groups and UV-absorbing radicals can be mixed independently of one another according to the general formula (I)...

20060188459 - Cosmetic, pharmaceutical or dermatological preparations comprising copolymer waxes: Cosmetic, pharmaceutical and dermatological preparations are described which contain copolymer waxes. The copolymer waxes contain structural units which are derived from α-olefins having 26 to 60 carbon atoms, from maleic anhydride, maleic acid or salts thereof and optionally from further monomers....

20060188460 - Solid hair conditioning product: A cosmetic product (1) for conditioning hair, the cosmetic product having the form of a solid and comprising at least one hair conditioning ingredient. Cocoa butter, cetearyl alcohol (and) sodium lauryl sulfate and glyceryl stearate (and) PEG 100 stearate are used to form the solid and the at least one...

20060188461 - Linear sulfonic polyester as a water-resistant hair fixing agent: The present patent application relates to the use of at least one water-dispersible linear sulfonic polyester as a hair fixing agent that is resistant to liquid water....

20060188462 - Skin care compositions containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060188466 - Cosmetic composition comprising at least one fixing polymer and at least one amphoteric starch: A cosmetic composition for the treatment of keratinous fibres, in particular hair, comprising at least one fixing polymer and at least one amphoteric starch and the process for treatment of keratinous fibres using said composition....

20060188465 - Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols: The invention discloses a cross-linked polymer of at least one carbohydrate component comprising at least one primary alcohol function in particular for the manufacture of a composition which is intended to be applied onto the skin to obtain a tensing and/or toning effect....

20060188464 - Microencapsulation systems and applications of same: The invention relates to microencapsulation systems which are characterised in that they are developed from oily substances or sugars and in that they form an essentially organised assembly corresponding to stacks of crystalline structures. The inventive systems can be used for the microencapsulation of one or more substances which are...

20060188467 - Skin care composition containing a sugar amine: Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of...

20060188463 - Stable water-in-oil-in-water multiple emulsion system produced by hydrodynamic dual stabilization and a method for preparation thereof: The present invention relates to a water-in-oil-in-water multiple emulsion system and a method for preparation thereof, characterized by hydrodynamically stabilizing the multiple emulsion system by using hydrodynamic dual stabilization (HDS) technology. The HDS technology hydrophobizes water molecules in the internal aqueous phase by using a hydrogen bonding inhibitor and by...

20060188468 - Cosmetic and pharmaceutical substances based on polyelectrolyte complexes: The present invention relates to cosmetic and pharmaceutical compositions which comprise at least one polyelectrolyte complex which comprises a copolymer with cationogenic groups based on vinylimidazole and an acid-group-containing polymer. The invention further relates to the use of these polyelectrolyte complexes....

20060188469 - Vaccine delivery compositions and methods of use: The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion...

20060188470 - Pes 2000 plus folic acid: 1. A therapeutic dose of PES 2000 when taken orally by animals or humans helps to control and prevent epilepsy....

20060188473 - Compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disorders: The invention provides isolated regulatory immune cells as well as cell cultures and conditioned media derived therefrom. Also provided are methods of repressing B cell autoantibody production and/or secretion and methods of treating autoimmune disorders using regulatory immune cells or precursors thereto. Further provided are methods of diagnosing in a...

20060188472 - Has-active ingredient conjugates: The invention relates to compounds comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate,...

20060188471 - Methods of treating epithelial lesions: The invention features methods of preventing or treating epithelial cell lesions in a mammal by administering a composition containing a therapeutically effective amount of a trefoil domain-containing polypeptide, or a trefoil peptide fragment, and a mucoadhesive excipient. The invention further features methods of preventing or treating an eye disorder, e.g.,...

20060188474 - Interleukin 1beta protease and interleukin 1beta protease inhibitors: wherein R1 and R3 are independently any D or L isomer amino acid, R2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1β protease activity are also disclosed. The inhibitor compounds comprise an amino...

20060188476 - Interleukin 20 (il-20) and its use in neovascularisation: The invention provides a novel method of regulating neovascularisation....

20060188475 - Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders: Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed....

20060188478 - Glycosylated interferon: This invention provides for human interferon-α which includes novel glycosylation structures....

20060188477 - Use of interferon alpha 5 in the treatment of viral liver diseases: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the...

20060188479 - Adenovirus vectors containing cell status-specific response elements and methods of use thereof: The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using...

20060188482 - Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal: Methods for introducing recombinant adeno-associated virus (rAAV) virions into the liver of a mammal are provided. In these methods, the liver is partially or completely isolated from its blood supply, a catheter is introduced into the liver via a peripheral blood vessel, and rAAV virions are then infused through the...

20060188481 - Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder: The invention is directed to a method of prophylactically or therapeutically treating an animal for an ocular-related disorder. The method comprises administering to an eye of the animal an expression vector comprising a nucleic acid sequence encoding an adenoviral-responsive gene product. The expression vector transduces a host cell and the...

20060188480 - Viral vectors: The present invention provides a herpes virus which lacks a functional ICP34.5 encoding gene and which comprises two or more of—(i) a gene encoding a prodrug converting enzyme; (ii) a gene encoding a protein capable of causing cell to cell fusion; and (iii) a gene encoding an immunomodulatory protein....

20060188483 - Virus vectors and methods of making and administering the same: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors....

20060188484 - Virus vectors and methods of making and administering the same: The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors....

20060188489 - Methods and materials for increasing potency of cells: Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent...

20060188490 - Transfection of blood cells with mrna for immune stimulation and gene therapy: The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region...

20060188491 - Use of nuclear material to therapeutically reprogram differentiated cells: Methods are provided for therapeutically reprogramming differentiated cells with nuclear extracts from pluripotent stem cells to generate a pluripotent epigenetic state in the differentiated cells. Additionally, therapeutically programmed cells for therapeutic use in patients are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent...

20060188485 - Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations: The invention relates to cells of monocytic origin suitable for the prevention and/or treatment of diseases associated with disturbed self-tolerance, in particular autoimmune diseases and allergies, and to pharmaceutical preparations containing these cells. The cells are autologous in relation to the patient to whom they are to be administered. The...

20060188487 - Blend hydrogels and methods of making: The present invention provides blend water-swellable materials and hydrogels suitable for use in biomedical or other applications. The blend water swellable materials and hydrogels have at least one hydrophilic polymer and at least one other polymer or oligomer having both hydrophobic and hydrophilic recurring units where the blend phase separates...

20060188488 - Prevascularized constructs for implantation to provide blood perfusion: This application discloses methods and materials for preparing functional microvascular beds in the laboratory. These prevascularized constructs can be used to vascularize engineered tissue constructs or to revascularize damaged or diseased tissues or organs following implantation. The prevascularized constructs may also deliver genetically engineered gene products to the bloodstream....

20060188486 - Wound care polymer compositions and methods for use thereof: The present invention provides wound healing or wound care polymer compositions that can be formulated to release a wound healing agent at a controlled rate by adjusting the various components of the composition. The compositiona can be used in an external wound dressing, as a polymer implant for delivery of...

20060188492 - Topical management of ocular and periocular conditions: Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide/endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents...

20060188497 - Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase...

20060188496 - Intranasal administration of active agents to the central nervous system: A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a...

20060188494 - Method for treating established spontaneous auto-immune diseases in mammals: A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance....

20060188495 - Treatment method: The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient....

20060188493 - Use of an active substance that binds to cd28 for producing a pharmaceutical composition: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimic compound of the same for producing a pharmaceutical composition for the induction and/or reproduction of regulatory T-cells....

20060188501 - Diagnostic and therapeutic agents for rheumatoid arthritis: The present invention provides a therapeutic agent for rheumatoid arthritis which inhibits the growth of synoviocytes mediated by c-erbB-2 by clarifying the participation of c-erbB-2 in the growth of synoviocytes in rheumatoid arthritis patients and inhibiting the activation or expression of c-erbB-2....

20060188500 - Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population....

20060188499 - Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne...

20060188498 - Methods of using death receptor agonists and egfr inhibitors: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with...

20060188502 - Anti-il-6 antibodies, compositions, methods and uses: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions,...

20060188504 - Interleukin-13 as a cardiovascular disease marker: The present invention relates to use of interleukin-13 as a cardiovascular disease marker. The therapeutic composition and diagnostic composition of the invention for cardiovascular diseases are characterized by comprising an antibody to an interleukin-13 receptor and/or an antibody to interleukin-13....

20060188503 - Modulation of enos activity and therapeutic uses thereof: The present invention provides uses of VEGF or VEGF receptor agonists for the up-regulation of eNOS expression and activity. VEGF and VEGF receptor agonists are useful in the treatment of or prevention from hypertension, diabetes, angina, thrombosis, atherosclerosis, heart failure, and other conditions or disorders wherein nitric oxide is an...

20060188505 - Treatment of autism: The invention includes methods of treating autistic spectrum disorders, including autism, in a patient where the method includes administration of an inhibitor of gamma interferon, an inhibitor of IL-1 beta, an inhibitor of IL-6, an inhibitor of IL-12, an inhibitor of IL-18, an inhibitor of TNF-alpha, and the administration of...

20060188510 - Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell...

20060188509 - Extending time to disease progression or survival in cancer patients: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab....

20060188508 - Methods and compositions for modulating angiogenesis: Methods and compositions for modulating angiogenesis in a subject are provided. Aspects of the invention include administering an effective amount of a TXR1 modulatory agent, e.g., a TXR1 agonist or antagonist, to a subject. Embodiments of the methods find use in a variety of different applications, including the inhibition of...

20060188507 - Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors: Disclosed are methods for detecting adriamycin resistance in a test neoplastic cell from a non-hematological cancer. The methods include detecting a level of p16 expression in the test neoplastic cell of a given origin or cell type, and comparing the level of p16 expression detected in the test neoplastic cell...

20060188506 - Therapy-enhancing glucan: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance. which could be...

20060188511 - Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be...

20060188512 - Active immunization to generate antibodies to solble a-beta: The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer's disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit...

20060188513 - Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians: The present invention provides novel compositions of matter comprising MAP compositions comprising at least 2 inhibin-related peptides linked to a backbone. These compositions are immunogenic and enhance production performance when administered together with an acceptable carrier to animals, especially avians....

20060188516 - Chlamydia trachomatis antigens: The present invention relates to antigenic proteins from Chlamydia trachomatis. A method for inducing an immune response with an immunogenic Chlamydia protein is provided in which an effective amount of an immunogenic Chlamydia protein is administered to a subject. In one example, the immunogenic Chlamydia protein has a molecular weight...

20060188515 - Polypeptides for inducing a protective immune response against staphylococcus aureus: The present invention features hybrid polypeptides providing ORF0657n and ORFO190 epitopes, nucleic acid encoding for the different polypeptides, and a method for evaluating the ability of an immunogen to produce a protective immune response against Staphylococcus infection. ORF0657n and ORF0190 are both S. aureus proteins....

20060188514 - Products specific to pathogenic strains and their use as vaccines and in immunotherapy: The invention relates to isolated antigenic polypeptides obtainable by a process comprising the steps of: 1—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria, 2—identifying the genes coding for said polypeptides which are conserved in B2/D...

20060188517 - Mycobacterial sulfation pathway proteins and methods of use thereof: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or...

20060188518 - Glycoconjugate vaccines for use in immune-compromised populations: Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals...

20060188519 - Peptides, antibodies, and methods for the diagnosis of sars: The present invention discloses 27 immunoreactive peptides and antibodies immunologically reactive with said peptides. Such peptides and antibodies can be used for diagnosis of SARS-CoV infection as well as for preparing vaccination against SARS-CoV or a closely related coronaviruses....

20060188520 - Protective antigen of epstein barr virus: The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T...

20060188521 - Treatment of t cell disorders: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC)....

20060188522 - Viral agents: A viral DNA construct, and virus encoded thereby, is provided having one or more tumour specific transcription factor binding sites in place of one or more wild type transcription factor binding sites operatively positioned in the promoter region which controls expression of early genes responsible for viral nucleic acid replication....

20060188524 - Canine vaccine for protection against ehrlichiosis: The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent....

20060188523 - Methods for diagnosing and treating chronic tonsillitis: The invention relates to diagnostic methods, therapeutic methods and kits for diagnosing and treating chronic adenotonsillar tonsillitis and adenotonsillar hypertrophy as well as vaccines for preventing chronic adenotonsillar tonsillitis and adenotonsillar hypertrophy....

20060188525 - Transdermal botulinum toxin administration for the treatment of spastic muscle pain: Pharmaceutical compositions for transdermal administration of neurotoxins to a patient include a neurotoxin, such as a botulinum toxin, and an enhancing agent that facilitates absorption of the neurotoxin through the skin of the patient and does not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied...

20060188526 - Method for enhancing the immune response to staphylococcus aureus infection: A method for enhancing the immune response of a patient to Staphylococcus aureus infection comprising administering to said patient an effective amount of agent that inhibits the cofactor that mediates (1) the removal of C3b by factor I from Staphylococcus aureus cells to which it has bonded by factor I...

20060188527 - Methods for vaccinating against malaria: The invention pertains to methods for protecting against malaria infection by vaccination. The method of the invention involves priming an anti-malaria immune response with a DNA-based vaccine and boosting that response with a protein-based a vaccine. The method of the invention also relates to broadening the resulting immune response by...

20060188530 - Bile preparations for gastrointestinal disorders: The present disclosure relates to methods and compositions to offset, ameliorate and/or alleviate one or more unwanted and/or adverse gastrointestinal effects. For example, in some embodiments, the present disclosure relates to compositions that include a bile acid, a carbohydrate and/or a pharmaceutical compound, wherein the pharmaceutical is associated with an...

20060188531 - Mixture for transdermal delivery of low and high molecular weight compounds: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed....

20060188532 - Mixture for transdermal delivery of low and high molecular weight compounds: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed....

20060188528 - Spreadable warming lubricant: A substantially anhydrous, spreadable warming lubricant composition comprising a mixture of glycerin, a polyhydric alcohol, and a non-ionic surfactant, the viscosity of the composition being less than that of glycerin but greater than that of the polyhydric alcohol, thereby promoting formation of a useful thin layer on a surface with...

20060188529 - Stable compositions of fenofibrate with fatty acid esters: A pharmaceutical composition in unit dose form of fenofibrate and a solvent system of fatty acid esters, wherein the fenofibrate is substantially dissolved in the solvent system....

20060188533 - Delivery of bio-available compounds with anhydrous topical preparations: The disclosed systems and methods for delivery of bio-available compounds in topical preparations generally include anhydrous carrier particles adapted to carry bio-available compounds. The carrier particles may be admixed with anhydrous formulation material that is suitably adapted to suspend and/or separate the carrier particles. Disclosed features and specifications may be...

20060188534 - Dispersions for the formulation of slightly or poorly soluble agents: The invention provides a dispersion having an oily phase, an aqueous phase, in the form of an oil-in-water emulsion or a water-in-oil emulsion, and at least one active ingredient that is only slightly or with difficulty soluble in the oily phase and the aqueous phase. The dispersion is free from...

20060188537 - Generation of antimicrobial surfaces using dendrimer biocides: A silane-QAC-dendritic polymer biocide surface treatment for bath, screen or spray-on application. The silane-QAC-dendritic polymer biocide generally comprises a hyperbranched polymer modified to include functionalized quaternary ammonium for biocidal activity, and further modified to include a functionalized silane moiety to covalently attach the polymer biocide to a variety of substrates...

20060188535 - Method of controlling aquatic insects: The control of aquatic insects can be accomplished by the careful application of an insect control unit into a treatment site in a treatment locus. A careful application of a defined amount of pest control in a pest control unit can effectively control flying insects emerging from aquatic environments with...

20060188536 - Particles from processing of oleander leaves: A method for processing oleander leaves which produces finely processed oleander particles that will yield high levels of oleandrin when subjected to extraction techniques. The method utilizes washing, drying, and passing the oleander leaves through a comminuting and dehydrating apparatus that separates the particles according to size....

20060188538 - Wearable insect repelling patch: An insect repellent patch is disclosed of a size and weight compatible for wearing on the clothing or skin of a user. The patch has a gross area not in excess of 232 cm2 and bearing one or more insect repellents having a vapor pressure at 25° C. of not...

20060188540 - Insect attractant composition and trap containing same: An insect attractant composition including a short chain carboxylic acid, a short chain alcohol, a surfactant and water....

20060188539 - System for trapping flying insects with attractant lures: The present application discloses a system for trapping flying insects, utilizing carbon dioxide in conjunction with one or more biochemical lures, visual lures or both. Preferably, a biochemical lure such as lactic acid, a salt of lactic acid, or combinations thereof, are employed in particular geometric shapes contained in specifically...

20060188541 - Coating an implant for increased bone in-growth: A method of preparing an implant for bone in-growth comprising: providing a metal implant body, the metal implant body having a metal load bearing layer on an outer surface, the metal load bearing layer having a plurality of pores therein, the pores configured to promote bone in-growth into the load...

20060188542 - Implant improving local bone formation: A bone implant comprises an active agent on at least a portion thereof. The active agent is locally deliverable to bone proximate the implant in at least a two-phased release scheme. A first phase rapidly releases a first quantity of the active agent, and at least a second phase gradually...

20060188543 - Nanoparticle coating for drug delivery: Coatings for drug delivery. In particular, coatings comprising nanoparticles loaded with at least one drug, on implants such as stents, to deliver drugs at the sites of implantation....

20060188544 - Periodontal tissue regeneration using composite materials comprising phosphophoryn: This invention relates to composite biomaterials having a sponge-like structure and comprising phosphophoryn and collagen, and to periodontal tissue regeneration....

20060188547 - Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices: or the diamines and diisocyanates thereof, wherein each X represents a member independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO— where y is one of the numbers 2, 3, 4 or 6-24 inclusive, and —(CH2CH2O)z′CH2COO— where z′ is an integer between...

20060188545 - Bioabsorbable composition and coatings including same: Bioabsorbable compositions of A) blends of bioabsorbable homopolymers and/or copolymers containing glycolide and lactide and B) salts of fatty acids and/or fatty acid esters are described. Processes for making the compositions and surgical articles made totally or in part therefrom, including suture coatings, are also described....

20060188546 - Medical devices employing novel polymers: Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain...

20060188548 - Satiety promoting beverage and use in a diet to moderate food consumption: A satiety promoting beverage and a weight control regimen using it are described comprising: fiber, protein, sweetener and preferably calcium and a catechin, such as purified epigallocatechin gallate derived from green tea. The ingredients are employed in amounts sufficient that a single serving provides a feeling of satiety, both initially...

20060188549 - Animal feed compositions capable of reducing the incidence of fescue toxicosis in mammals: Animal feed compositions having utility in reducing the incidence of and treating the symptoms of fescue toxicosis in mammals that consume endophyte-infected fescue are disclosed. Methods of reducing the incidence of fescue toxicosis and making animal feed compositions are further disclosed....

20060188550 - Method of production of animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response: A process of producing, collecting, increasing the volume, processing, standardizing, stabilizing, sterilizing and drying bacterial polysaccharides while retaining the activity of the contained bacterial polysaccharides is described. Nutritional compositions including the resulting product, probiotics, nutricines, vitamins, minerals, an amino acid, and a monosaccharide are depicted. The use of the product...

20060188553 - Facial cosmetic devices: An eyeliner element adapted to be applied to a lower portion of an upper eyelid, and an under eye concealer element adapted to be applied to an upper portion of a lower eyelid each include a thin film substrate, an adhesive layer, and a coloring layer formed opposite the adhesive...

20060188552 - Method of manufacturing a hand health care glove: A process for creating a disposable glove which has been specially treated with a uniform coating of the Lanolin and Vitamin-E composite through a specially controlled application and drying process. The process satisfies the need to minimize the side effects of skin damage and irritation due to prolonged and extensive...

20060188551 - Products comprising a sheet and a wax dispersion: This invention concerns products for cleansing and other applications that comprise a sheet of absorbent material, in particular of non-woven material, such as a wipe, to which are applied a wax dispersion and an aqueous phase. The invention further concerns the manufacture and use of such products....

20060188555 - Therapeutic peptide formulations with improved stability: Compositions of and methods for formulating and delivering peptide, polypeptide and protein therapeutic agent formulations having enhanced physical stability, and wherein fibril formation is minimized and/or controlled, to yield a consistent and predictable composition viscosity. The compositions of and methods for formulating and delivering peptide, polypeptide and protein therapeutic agents...

20060188554 - Transdermal absorption preparation: (Solving means) A composition comprising KRP-197 and an external preparation base is deposited and dried onto a structural body or a small pool of the composition is deposited on the structural body to obtain a single adhesive layer-type transdermal preparation or a reservoir-type transdermal preparation. These preparations can ensure high...

20060188556 - Ultrasonically assisted dermal or transdermal delivery substance preparation: A method for improving transdermal delivery of an active ingredient in a formulation made in accordance with a dibasic sodium phosphate containing formula responsively to insonification thereof, including: reducing the amount of dibasic sodium phosphate in the formula to provide a reduced dibasic sodium phosphate formula; and, making a formulation...

20060188557 - Prepartaion for external percutaneous administration containing non-steroidal anti-inflammatory drug and interleukin-1 alpha production inhibitor: A transdermal formulation for external application comprising a non-steroidal anti-inflammatory analgesic, an alkyl ester of gallic acid, and a phenolic radical scavenger having a branched-chain lower alkyl group. An interleukin-1α production inhibitor consisting of a phenolic radical scavenger having a branched-chain lower alkyl group, and/or an alkyl ester of gallic...

20060188558 - Transdermal systems having control delivery system: Transdermal delivery systems are disclosed including a backing layer, a polymer membrane within the backing layer, an adhesive layer for attaching the delivery system to the patient's skin or mucosa, and a releasable layer covering the adhesive layer prior to use, the polymer membrane impregnated with sufficient fluid medium to...

20060188560 - Delivery system for nucleic acids: αvβ3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic αvβ3 integrin antagonist....

20060188562 - Materials and methods for drug delivery and uptake: The subject invention pertains to novel materials and methods for use in delivering and sequestering substances, such as pharmacological agents, within a patient. One aspect of the invention is directed towards core-shell particles having a core encapsulated within a calcium carbonate shell, with an intermediate layer composed of an amphiphilic...

20060188561 - Pharmaceutical compositions for lipophilic drugs: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms...

20060188559 - Topical cosmetic compositions comprising alpha arbutin: This invention is a topical tyrosinase inhibiting combination using alpha arbutin and bearberry extract, in synergism, for the purpose of skin lightening. The active admixture is a dermatological serum comprised of alpha arbutin, octyl stearate and polyolprepolymer-2, introduced onto the human skin in liposome form for ultra-deep penetration....

20060188564 - Cellulose hard capsule enhancing mechanical film strength: This invention provides a process for preparing a cellulose capsule enhancing mechanical film strength comprising the steps of: i) preparing a mixed solution of iota-carageenan and agar; ii) adding said mixed solution to an aqueous solution of solubilized cellulose; iii) adding sucrose fatty acid ester, potassium pyrophosphate and glacial acetic...

20060188563 - Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis: A medicinal oral preparation to be delivered to the large intestine comprising a core containing a pharmacologically active ingredient, an inner layer containing one or more cationic polymers and an outer layer containing one or more anionic polymers whereby the core is coated, which is designed so that, in a...

20060188566 - Nanoparticulate formulations of docetaxel and analogues thereof: Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can be used in the treatment of cancer....

20060188565 - Rapidly bioavailable tablet and capsule formulations of diclofenac: The present invention relates to excipients for the production of rapidly bioavailable solid oral dosage forms of diclofenac. In particular, the invention relates to the use of excipients that promote the bioavailability of such formulations, including alkaline buffering agents, gas forming excipients, hygroscopic excipients, water soluble diluents, wetting agents, and...

20060188567 - Gelatin hard capsule enhancing the film strength: The present invention relates to a process for preparing gelatin hard capsule having enhanced film strength by the steps comprising; i) adding 1˜10 wt part of PEG mixture of PEG 600 and PEG 1500 in weight ratio 40˜60:60˜40 to the solution having 100 wt part of gelatin; ii) adding 0.1˜1.2...

20060188570 - Compressed tablet formulation: This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS....

20060188568 - Stable formulations of ace inhibitors and methods for preparation thereof: Stabilized pharmaceutical solid composition of ACE inhibitor comprising an ACE inhibitor and a selective dosage formulation thereof comprising of meglumine. The ACE inhibitor selectively combined with a dosage form including essentially the meglumine is surprisingly found to avoid the degradation of ACE inhibitor by such dosage forms especially the commonly...

20060188569 - Stable pharmaceutical formulations of zonisamide and methods for their manufacture: One of the embodiments of the present invention is directed toward a process for preparing a stable zonisamide pharmaceutical composition, comprising subjecting zonisamide to wet granulation with a granulation liquid to form a granulated mixture as the stable zonisamide pharmaceutical composition, wherein the granulation liquid is selected from purified water,...

20060188571 - Vaginally administrable progesterone containing tablets and method for preparing the same: The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the...

20060188573 - Composite materials and particles: A method or concept for producing a composite material having at least an amphifilic (i.e., surface-active) and polymer component, and the composite material formed thereby, includes providing a mixture of at least one each of polymer and amphifilic compound in a volatile solvent or solvent mixture and providing a phase...

20060188574 - Controlled release lipoic acid: A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels...

20060188572 - Controlled release of s-methoprene and other active ingredients with activated carbon: An effective controlled release pest control composition can use activated carbon as the sole release agent. Liquid pesticide is adsorbed into the interior mesopore and macropore space of the activated carbon. Upon contact with water, the pesticide is slowly displaced from the carbon into the environment for appropriate control. The...

20060188575 - Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that...

20060188576 - Pirenzepine ophthalmic gel: It is a primary object of the present invention to provide an aqueous ophthalmic formulation, for treating myopia, comprising pirenzepine in combination with a pharmaceutically acceptable gel carrier....

20060188580 - Anti-microbial granules: Antimicrobial granules comprising granular materials coated with antimicrobial metal agents for use in various surface coating and grouting materials are provided. The antimicrobial granules have utility in imparting durable, safe, inexpensive and powerful antimicrobial properties to materials into which they are incorporated, such as epoxy coating and grouts for surgical...

20060188577 - Element having bioactive substance fixed thereto: By using a biologically active substance-immobilized device, which comprises a base particle comprising a core particle and an organic compound having two or more hydrophilic groups and immobilized on the core particle by a chemical bond and a biologically active substance bonded to the base particle via the organic compound,...

20060188578 - Hyaluronic acid nanoparticles: The invention relates to hyaluronic acid nanoparticles for the administration of at least one active ingredient. The inventive nanoparticles comprise hyaluronic acid in salt form a positively-charged polymer, a polyanionic salt and at least one active ingredient. The method of obtaining the aforementioned nanoparticles comprises the following steps consisting in:...

20060188579 - Novel process: The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution....

20060188581 - Rasagiline formulations of improved content uniformity: Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses....

20060188582 - Double walled microcapsules with an outer thermoplastic wall and application process thereof: The present invention concerns double-walled microcapsules with an outer thermoplastic wall and an application process thereof on substrates, namely textile substrate. The microcapsules are applied to fibres so as to produce a slow release of products such as fragrances, antimicrobial, insecticides, antioxidants, vitamins or they can be used as materials...

20060188583 - In situ controlled release drug delivery system: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or...

20060188584 - Composition and process for treating acne: A composition and process is disclosed for treating an acne infection with a composition of electrolytically generated silver citrate. The composition of electrolytically generated silver citrate may be applied topically to the acne infection in an aqueous solution or may be incorporated within a cosmetic product. The acne composition may...

20060188586 - Compositions and methods for enhancing therapeutic effects: Compositions and methods for enhancing the effects of therapeutic compositions are provided. The compositions comprise singly or in combination herbals, natural nutritional supplements, minerals and vitamins. Methods of making these compositions are also provided....

20060188585 - Nerium oleander extract: The present invention is directed to γ-Interferon-inducing activity of Nerium oleander, special extract, its ingredients, and compositions containing fixed combinations of the Nerium oleazide, and Glycyrrhiza glabra special extracts, as well as to a method of preparation of these extracts using a substance's characteristics infonnation transmission technique....

20060188587 - Cranberry processes and products: In embodiments, cranberries are utilized at certain phases of development, prior to full red color development, which are typically characterized by an acid profile conducive to producing flavorful, high-value products, such as juices. At select phases of development, the berries have a quinic acid content which is similar to fully...

20060188588 - Herbal preparation to relieve inflammation and smooth muscle contraction: An herbal preparation comprised of sage, thyme and cumin is found to relieve the symptoms of inflammation and smooth muscle contraction. The preparation preferably comprises sage, thyme and cumin in the proportions 0.50, 0.43 and 0.07 respectively. The symptoms of menstrual cramps and asthma are relieved by administration of the...

20060188589 - Oral care compositions derived from the labiatae family: The invention relates to water dispersible extract preparations derived from water soluble components of Labiatae family plant material, including plant material hay and previously extracted or spent hay, which possesses beneficial oral care properties, methods of their manufacturing and application of the preparations in oral care products....

20060188590 - Compositions for treating diabetes or obesity: This invention relates to a composition that includes two compounds selected from a group of nine members, i.e., an α-glucosidase inhibitor, an intestinal glucose transporter inhibitor, a glycation inhibitor, a nitric oxide production inhibitor, an aldose reductase inhibitor, a PPAR agonist, an adipocytokine activator, a glucose uptake enhancer, and a...

20060188591 - Bauhinia extracts: The present invention relates to an plant extract from Bauhinia species with hypoglycemic activity, which is characterized in being obtained from a Bauhinia species and to a method for producing the extract and the use of the extract in the treatment of diabetes type 2....

20060188592 - Cyclooxygenase-3 inhibitory withanolide compositions and method: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1....

20060182682 - Diagnosis of prostate cancer: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies,...

20060182683 - Methods for reduced renal uptake of protein conjugates: Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof....

20060182684 - Method for transporting a compound across the blood-brain barrier: The present invention relates to improvements in the field of drug delivery. More particularly, the invention relates to a non-invasive and flexible method and carrier for transporting a compound or drug across the blood-brain barrier of an individual. In particular the present invention relates to a carrier for transporting an...

20060182686 - Developmental animal model of temporal lobe epilepsy: Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the...

20060182685 - Hollow fiber technique for in vivo study of cell populations: The present invention relates to a method of using hollow fibers to evaluate cellular changes in vivo. A method for evaluating cellular changes in vivo in response to administration of a drug or drugs of interest is provided. The hollow fiber technique is also used to evaluate cellular changes in...

20060182687 - Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications: Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1-Y-X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided...

20060182688 - Metronidazole-based tinted topical pharmaceutical compositions: Topically applicable pharmaceutical compositions suited for the treatment of dermatological complaints, conditions or afflictions, notably rosacea, contain a thus effective amount of metronidazole and at least one dye effective to impart a green color thereto, formulated into a topically applicable, pharmaceutically acceptable vehicle therefor....

20060182690 - Alcoholic pump foam: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam...

20060182689 - Process for separating out at least one organic compound: Process for separating out at least one organic compound from a substrate containing the said organic compound, comprising a treatment of the substrate with an extraction medium comprising at least one fluoro compound with an atmospheric boiling point of greater than or equal to 25° C., so as to form...

20060182692 - Chemically modified small molecules: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a...

20060182691 - Impregnated powder improving bioavailability and/or the solubility and method of production: This invention relates to an impregnated powder for increasing the bioavailabilty and/or the solubility of at least one active principle comprising a solid, inert support in a particle form impregnated by a liquid medium comprising a hydrophobic phase and optionally a hydrophilic phase, at least one surfactant and at least...

20060182693 - Chewing gum possessing tooth cleaning effect and a teeth cleaning method: The invention relates to a chewing gum possessing tooth cleaning effects, excluding the tooth brush abrasive effect, which chewing gum when chewed on a daily basis as a tooth cleaning agent is capable of replacing the daily tooth brushing, whereby abrasive cleaning damages on teeth side surfaces and gingiva are...

20060182694 - Oral composition: An oral composition comprising perlite characterised in that the oral composition comprises chalk....

20060182695 - Peroxidase-activating oral compositions: A peroxidase-activating oral care composition, in accordance with an embodiment of the invention, includes a non-enzymatic, water-soluble hydrogen peroxide precursor and a pH-adjusting agent capable of producing a selected pH in an aqueous solution. The composition facilitates the rapid release of hydrogen peroxide and results in the activation of a...

20060182697 - Composition for treating keratin fibers, comprising at least one aromatic alcohol, at least one aromatic carboxylic acid, and at least one protecting agent: Disclosed herein is a cosmetic composition comprising, in a physiologically acceptable aqueous medium: at least one agent for protecting keratin fibers; at least one aromatic alcohol; and at least one aromatic carboxylic acid or a salt thereof. Also disclosed herein is a method for protecting keratin fibers against the action...

20060182696 - Water-soluble anti-dandruff compounds and compositions thereof: Water-soluble and water dispersible undecylenic amido propyl dimethyl hydroxyl ethoxy ethyl ammonium undecylenate compounds of formula I having anti-dandruff, preservative and sunscreen activity wherein R1, R2 are from C1-C6 carbon atoms, R3 is undecylenic acid, amino group is selected from dimethyl amino propyl amine. Personal care compositions comprising compounds of...

20060182699 - Personal care compositions containing hydrophobically modified non-platelet particles: A rinsable personal care composition includes (a) 0 to 75 weight percent of a composition surfactant; (b) 0.01 to 99 weight percent of a skin benefit agent or emollient; (c) 0.01 to 20 weight percent of a hydrophobically modified non-platelet particle; and (d) 0 to 99% water....

20060182698 - Preparation of chromium oxide pigment with reduced chromium (vi) content: The invention relates to a method for preparing pigmentary composition of particles based on hydrated chromium oxide for cosmetic use in which chromium is embodied in the form of chromium (VI) in a quantity equal to or higher than 5 ppm with respect to a total mass of said particles...

20060182703 - Blocky hydroxyethylcellulose, derivatives thereof, process of making, and uses thereof: This invention relates to non-uniformly substituted (“blocky”) hydroxyethylcelluloses (HECs) and derivatives thereof that exhibit associative behavior in both neat solutions and in filled systems. The HECs and derivatives thereof exhibit unique and highly desirable rheology and are more efficient in thickening aqueous systems than prior art HEC products. These blocky...

20060182700 - Cold wax depilatory composition and related process: A method of preparing a depilatory composition includes placing a quantity of sucrose into a heating vessel. Vinegar and citric acid are added into the heating vessel in the respective amounts of about 30 to 35% and 2.0 to 2.5% of the quantity of sucrose. The sucrose, vinegar and citric...

20060182702 - Composition containing a cation, a cationic polymer, a solid compound and a starch, and cosmetic treatment process: The present invention relates to a composition containing, in a cosmetically acceptable aqueous medium, at least one cationic surfactant, at least one starch, preferably a modified starch, at least one non-silicone cationic polymer with a particular cationic charge and at least one nonionic non-polymeric solid compound with a melting point...

20060182701 - Tissue culture media used as a component of cosmetics: A cosmetic or dermatological preparation which comprises one or more tissue culture media, in particular one or more skin cell culture media....

20060182705 - Composition for reduction and prevention of wrinkles on the skin: A composition for reducing and preventing wrinkles on the skin is disclosed. The composition is provided in the form of an aqueous gel containing papain, urea, boric acid, preservatives, the sodium salt of 2-pyrrolidone-5-carboxylic acid, and almond extract....

20060182704 - Disposable whole face mask for topical delivery of cosmetic, nutritional or medicinal preparations and for use with facial massage, acupressure and aroma therapies and the method of applying topical cosmetic, nutritional or medicinal preparations thereby: The invention describes a novel invention of a disposable mask which covers the entire face and is pre-moistened or impregnated with a cosmetic, nutritional or medicinal solution, preferably one beneficial to the skin; as well as the novel invention of the method of applying cosmetic, nutritional or medicinal solutions to...

20060182706 - Polymer products and their use in cosmetic preparations: The present invention relates to polymeric products obtainable by mixing (A) polymers which are obtainable by free-radical polymerization of (A-1) ethylenically unsaturated monomers in the presence of (A-2) unsaturated polyalkylene glycols with (B) silicones at a temperature greater than or equal to 30° C. In addition, the invention relates to...

20060182707 - Thickener for aqueous systems: A polymer comprising: (a) from 25% to 45% carboxylic acid monomer residues; (b) from 50% to 65% C2-C4 alkyl (meth)acrylate residues; (c) from 2% to 20% of residues of at least one of: (i) an alkyl (meth)acrylate, (ii) a vinyl alkanoate, (iii) an N-vinyl alkylamide, and (iv) an N-alkyl (meth)acrylamide,...

20060182708 - Prebiotically active plant extracts: The invention relates to plant extracts that have a prebiotic effect on skin, topical cosmetic and pharmaceutical compositions containing said plant extracts, and the use of said plant extracts and compositions, especially for treating the skin....

20060182709 - Treatment of landfill gas: The present invention relates to a method of abating hydrogen sulfide gas emitted by or generated in landfills. Certain embodiments of the present invention relate to contacting hydrogen sulfide gas with Fuller's earth or other carrier materials and metals such as silver, copper, iron, zinc or mixtures thereof, and other...

20060182710 - Amphiphilic block copolymer and pharmaceutical formulation comprising the same: An amphiphilic block copolymer and a pharmaceutical formulation comprising the same. The amphiphilic block copolymer comprises a poly(lactide) as a hydrophobic block and a poly(oxazoline) as a hydrophilic block....

20060182711 - Conjugates of an epo moiety and a polymer: Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient....

20060182712 - Ccr ligands for stem cell homing: Chemokines ligands to at least one of CCR1, CCR2, CCR3, or CCR5 can be used to home stem cells for therapeutic applications....

20060182714 - Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides: The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein....

20060182713 - Vaccine composition comprising interleukin-15 (il-15): Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine...

20060182716 - Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least...

20060182715 - Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics....

20060182719 - Erbb3 binding protein compositions and methods of use: A method of repressing a cell-cycle gene, which is regulated by an E2F transcription factor, in a cell, wherein the method comprises contacting the cell with a cell-cycle gene-repressing amount of ErbB3 binding protein (Ebp1); a method of inhibiting prostate cancer in a mammal, wherein the method comprises administering to...

20060182718 - Methods and compositions comprising dna damaging agents and p53: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in...

20060182717 - Vector for expressing alpha-n-acetyl-galactosaminidase and method of treating mps i by stereotactic injection into the brain of a mammal: A purified nucleic acid molecule which is capable of expressing a lysosomal enzyme wherein said nucleic acid molecule comprises at least a sequence coding for said lysosomal enzyme and a promoter highly active in the brain inserted upstream from said sequence....

20060182726 - Immunomodulating compositions, processes for their production and uses therefor: The present invention discloses compositions and methods for antigen-specific suppression of immune responses, including primed immune responses. In particular, the invention discloses antigen-presenting cells, especially dendritic cells, whose level and or functional activity of CD40, or its equivalent, is impaired, abrogated or otherwise reduced, and their use for treating and/or...

20060182727 - Lactic acid bacteria capable of stimulating mucosal immunity: The invention provides lactic acid bacteria selected from the group consisting of lactobacillus ONRIC b0239 (FERM BP-10064) and lactobacillus ONRIC b0240 (FERM BP-10065), and compositions containing the bacteria, the compositions being capable of stimulating mucosal immunity, and more specifically, the compositions in the form of foods or beverages or pharmaceutical...

20060182720 - Cell preparation and use of the preparation for treating joints and cartilage defects, and methods for the production thereof: The invention relates to a cell preparation for therapeutic and/or cosmetic use in humans and/or animals, containing: a) human or animal cells, which; b) had been cultured while using a substance or substance mixtures that activates) CD44 expression of these cells, and which present an increased CD44 expression of these...

20060182724 - Method for expansion of stem cells: A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population....

20060182721 - Method of preparing langerhans cell from cd14-positive cell being human peripheral blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-ss: This invention provides a method for preparing Langerhans cells from CD14-positive cells, which are human peripheral blood mononuclear cells. This method comprises culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF, and TGF-β....

20060182722 - Methods and materials for isolating isogenic islet cells: Compositions and methods for isolating and purifying islet cells are described. Islets obtained using such compositions and methods can be transplanted into diabetic patients....

20060182723 - Methods for treating refractory infections in neutropenic individuals: The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic compositions and methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by...

20060182725 - Treatment of tissue with undifferentiated mesenchymal cells: The present invention provides compositions and methods for correcting cosmetic, aesthetic, and degenerative defects in the skin, soft tissue, and bone of a subject. In particular, methods of the invention involve the injection or implantation of autologous UMC, fibroblasts, and/or keratinocytes into the tissue (e.g., subcutaneous tissue) adjacent or subadjacent...

20060182729 - Combat/training antioxidant micronutrient formulation and method of administration: The invention is directed to a method for administering antioxidant micronutrient formulations comprising certain multiple dietary and endogenous antioxidants, B-vitamins, vitamin D, and minerals at appropriate doses and dose-schedules, particularly chosen to reduce acute and long-term adverse effects of environmental and physical stressors and toxic chemicals in Operating Forces, e.g.,...

20060182728 - Methods for treating pervasive development disorders: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism...

20060182730 - Antiobesity agent using hen's egg antibody against digestive enzymes: Objects of the present invention are to provide an agent for inhibiting a digestive enzymes and an antiobesity agent having digestive-enzyme-inhibiting activity with high substrate specificity and having high safety. Provided is a composition comprising eggs produced by hens immunized with digestive enzymes or fragments thereof, or the processed products...

20060182731 - Nicotine in therapeutic angiogenesis and vasculogenesis: The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease....

20060182732 - Composition for mitigating a pernicious thrombotic event: A composition. The composition comprises aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine. The composition has a structural form of: a chewable form, a dissolvable form, a liquid form, a spray form, or a suppository form. The structural form is suitable for being introduced into the body of a...

20060182733 - Atp diphosphohydrolase (cd39) gene therapy for inflammatory or thrombotic conditions and transplantation and means there for: A method to render endothelial cells capable of inhibiting platelet and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding ecto-ATP diphosphohydrolase or an oxidation-resistant analog thereof, and expressing a protein having functional ecto-ATP diphosphohydrolase activity, such as the human CD39 protein, by said...

20060182734 - Methods for preparing low molecular weight heparin with modified heparinase iii: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention....

20060182735 - Thrombin preparations and process for their production: The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remove viruses, is described. Before or after the hydrophobic interaction chromatography it is also...

20060182736 - Transducible dna-binding proteins: Disclosed is a chimeric protein comprising: a) a plurality of zinc finger domains; and b) a heterologous protein transduction domain, effective for translocating the protein across a cellular membrane. The chimeric protein can be efficiently transduced into cultured eukaryotic cells in which they regulate specific target genes. Thus, artificial transcription...

20060182737 - Wet wipes including a composition for reduction and prevention of wrinkles on the skin: Wet wipes comprising a composition for reducing and preventing wrinkles on the skin is disclosed. The composition is provided in the form of an aqueous composition comprising containing papain, urea, boric acid, preservatives, the sodium salt of 2-pyrrolidone-5-carboxylic acid, and almond extract....

20060182738 - Medical device for analyte monitoring and drug delivery: The invention relates to an ingestible, implantable or wearable medical device comprising a microarray which comprises a bioactive agent capable of interacting with a disease marker biological analyte; a reservoir which comprises at least one therapeutic agent and is capable of releasing the therapeutic agent(s) from the medical device; and...

20060182739 - Protein purification: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants....

20060182740 - Buffered formulations for concentrating antibodies and methods of use thereof: The present invention provides a method for producing a concentrated antibody preparation that includes the steps of: (a) obtaining an initial antibody preparation that is an aqueous solution of antibodies and histidine or acetate buffer at a concentration in the range of from about 2 mM to about 48 mM;...

20060182742 - System and method for magnifying a humoral immune response: The present application relates, in general, to a system and/or method for detection and/or treatment....

20060182741 - Use of adcc-optimized antibodies for treating weak patients: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F...

20060182743 - Methods of treating skin disorders using an il-31ra antagonist: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist....

20060182744 - Anti-cd137 antibody as an agent in the treatment of cancer and glycosylation variants thereof: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of...

20060182745 - Anti-cd63 antibodies and methods of use thereof: CD63 inhibition of IgE-mediated degranulation in mast cells and in vivo inhibition of allergic processes are described. The invention is drawn to methods of treating allergic conditions and anaphylaxis in a mammal comprising administering an effective amount of an agent that inhibits a function of CD63....

20060182747 - Treatment of autism: The invention includes methods of treating autistic spectrum disorders, including autism, in a patient where the method includes administration of an inhibitor of gamma interferon, an inhibitor of IL-1 beta, an inhibitor of IL-6, an inhibitor of IL-12, an inhibitor of IL-18, an inhibitor of TNF-alpha, and the administration of...

20060182746 - Tumour necrosis factor binding ligands: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of...

20060182748 - Method of creating antivenom using emus: A method for creating an antivenom for snake bites comprising obtaining the venom from at least one poisonous snake, obtaining an adult ratite bird, injecting the adult ratite bird with the venom in appropriate amounts at appropriate intervals such that the ratite bird develops antibodies to the venom, extracting blood...

20060182750 - Process for preparing stable drug conjugates: The invention provides a process for preparing a conjugate comprising a cell binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell binding agent, which then is conjugated to a drug, as well as purification and holding steps, and optionally a tangential flow...

20060182749 - Therapies for cancer using rlip76: The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject...

20060182751 - Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use: The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including...

20060182754 - Abundant extracellular products and methods for their production and use: Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a...

20060182752 - Tri-block polymers for nanosphere-based drug or gene delivery: Biocompatible non-toxic polyarylate triblock copolymers having an A-B-A structure wherein each A is a water-soluble, hydrophilic polymer end block and the B middle block is an polyarylate oligomer. The polymers spontaneously self-assemble to form low CAC nanospheres having utility as transfection agents for gene delivery....

20060182753 - Vaccines: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses....

20060182755 - Novel composition and methods for the treatment of psoriasis: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis....

20060182756 - Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans: The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia burgdorferi OspC families A, B, I and K. In...

20060182757 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their...

20060182758 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their...

20060182759 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their...

20060182760 - Method for protecting living body from external factor and composition therefor: The objective is to provide a composition or a food material for protecting a living body from an external factor, which includes an extract from Agaricus Blazei Murill. The composition protects a living body through immunocompetent cells. The immunocompetent cells may be macrophages, and optionally, T cells. The immunocompetent cells...

20060182761 - Methionine salvage pathway in bacillus: The present invention relates to pathways for the synthesis and recycling of methylthioribose (MTR), applications in the fight against plant and vertebrate pathogens (including parasites and their vectors), application for the production of fine chemicals, and in fermentation industry. The present invention also relates to the identification of new drug...

20060182762 - enterovirus, vaccines, medicaments and diagnostic kits: The invention provides a new enteroviral species call EV79, and functional parts, derivatives and analogues of said virus. Proteinaceous molecules capable of specifically binding EV79, such as isolated or recombinant antibodies, are also herewith provided. A virus and/or proteinaceous molecule of the invention is particularly suitable for diagnosis of an...

20060182763 - Cd8 t cell epitopes in hpv 16 e6 and e7 proteins and uses thereof: The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to...

20060182764 - Vaccines containing ribavirin and methods of use thereof: The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described....

20060182765 - Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin: The present invention provides a method for enhancing an immunological response to an antigen. The method comprises administering to an individual a composition comprising an antigen and an isolated LT-IIa-B pentamer or a mutant thereof, or an isolated LT-IIb-B pentamer or a mutant thereof. The selected LT-II-B pentamer acts as...

20060182767 - High-potency botulinum toxin formulations: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of...

20060182766 - Stabilized protein compositions for topical administration and methods of making same: A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods...

20060182768 - Peptides and dna encoding the peptides useful for immunizations against coccidioides spp. infections: The present invention provides compositions of peptides and polynucleotides encoding the peptides, which peptides are useful for generating an immunological response in an individual and in therapeutic and diagnostic applications of infections due to pathogenic Coccidioides spp. fungi, such as C. immitis or C. posadasii....

20060182769 - Peptide sequences specific for the hepatic stages of p. falciparum bearing epitopes capable of stimulating the t lymphocytes: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or...

20060182770 - Cosmetic and cosmeceutical compositions for restoration of skin barrier function: Compositions, kits and methods are provided for restoring skin barrier function to skin exposed to environmental elements and/or in a pathological condition. In general, divalent cations such as calcium ions and/or magnesium ions are included in a physiologically acceptable medium. In some embodiments, divalent cations are balanced with monovalent cations...

20060182771 - Formulations for ocular treatment: Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of...

20060182773 - Emulsifier composition and transparent or translucent micro emulsions containing said emulsifier composition: The disclosed invention relates to an emulsifier composition containing hydrophilic and lipophilic emulsifiers, characterized in that the hydrophilic emulsifier is selected from at least one of the compounds of group (A) which consists of (A.1) products of the addition of 8 to 30 moles ethylene oxide onto C16-22 fatty alcohols,...

20060182772 - Method for the extemporaneous preparation of cosmetic compositions having the texture of a cream and compositions for carrying out said method: The invention relates to a method for the preparation of cosmetic compositions having the texture of a cream. Said preparation is made at the time when the composition is used and includes bringing the following elements into contact with each other: (A) a liquid phase; (B) a powder containing a...

20060182774 - Aerosol for controlling insect pests: An aerosol for disinsectization comprising a mixture comprising a disinfestant component, a solvent, and a propellant, and a pressure-resistant container provided with an actuator, wherein the mixture is contained in the pressure-resistant container, and wherein the solvent is contained in the mixture in an amount of from 0 to 10%...

20060182775 - Insect repellent: An insect repelling composition comprising a mixture of oils in desired amounts, by volume: 1) Lemon oil—as a purifier, in the range of 0-30%; 2) Lavender oil or “Lavendine”—as an anti-bacterial agent, which encourages healing, and for fragrance, in the range of 0-10%; 3) Geranium oil—as an antiseptic and for...

20060182776 - Sustained release pest control products and their applications: A method for applying a barrier to structures to prevent the infiltration of pest species (unwanted organisms) uses a (e.g., coating) composition formed from a polyurethane (e.g., film-forming) polymer system and a pellet comprising a pesticide incorporated into a sorbent and dispersed in the polyurethane polymer system. The composition protects...

20060182777 - Method of modulating drug release from a coated substrate: A method of modulating drug release from coated substrates by modulating the drying rate of the coatings on the substrates. Each coating is a mixture of a polymer, a solvent, and drug and the method includes modulating the release rate of the drug particles from the outer surface of the...

20060182779 - Side-chain crystallizable polymers for medical applications: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to...

20060182778 - Suture and graft delivery systems: A suture, graft, or suture/graft combination that functions as a drug delivery system. In one embodiment of the invention, a suture fabricated from a polymer material incorporates the therapeutic agent within its pores, and then osmotically delivers the therapeutic agent directly to the injury. In a second embodiment of the...

20060182782 - Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same: A polymer coating for medical devices based on polyorthoesters and methods for fabricating the coating are disclosed....

20060182781 - Methods for treating ocular conditions with cyclic lipid contraining microparticles: Biocompatible microparticles include a ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can...

20060182780 - Resorbable hollow devices for implantation and delivery of therapeutic agents: A method of manufacturing a resorbable balloon designed to contain bone cement for vertebroplasty or kyphoplasty applications is described. The resorbable balloon can be inserted into a vertebral body following vertebral cavitation and filled with bone cement. The balloon remains in place in the vertebral body and resorbs over time....

20060182783 - Sustained release intraocular drug delivery systems: Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its...

20060182784 - Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis: The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to 1:150. The invention also relates to a terapeutical composition comprising a protein hydrolysate and a synthetic emulsifier and/or a...

20060182785 - System and method for producing foie gras in poultry: A method for producing poultry with CLA enhanced nutritional properties includes preparing a CLA containing diet, selecting a poultry species, feeding the CLA containing diet to the selected poultry species and harvesting at least one of a plurality of CLA enhanced poultry products. A system for producing poultry with CLA...

20060182786 - Transmucosal form of administration with reduced mucosal irritation: The present invention relates to film-shaped administration forms for transmucosal administration of active substances to the human or animal body. The administration forms are characterized by an adaptation or approximation of the pH value of the base mass intended for the production of the administration form to the physiological pH...

20060182787 - Skin or wound pad containing encapsulated substances which promote the healing of wounds and/or are used for skin care: A skin or wound contact material which comprises a polycondensate matrix and a water-absorbing polymer incorporated therein. The water-absorbing polymer is doped with a wound healing promoter substance and/or a skin care substance....

20060182789 - Apparatus and method for transdermal delivery of epoetin-based agents: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In...

20060182790 - Dermal medicaments application enhancer: A topical medicament for use in treating tissues comprising: an enhancer for facilitating non-invasive, transdermal delivery and/or enhancing metabolic effect of a therapeutic dosage of LEVULAN® KERASTICK™ (aminolevulinic acid HCl) into a tissue. The present invention provides a topical, transdermal medicament for use in treating tissues comprising an enhancer for...

20060182788 - Hydrophilic biocompatible adhesive formulations and uses: This invention relates to the use of hydrophilic, biocompatible adhesives in drug delivery systems, wound dressings, bioelectrodes, and other systems in which hydrophilic, biocompatible adhesives are desirable. In particular, the invention relates to water-swellable, water-insoluble polymers that in combination render a composition adhesive upon contact with moisture, wherein a first...

20060182791 - Transdermaltherapeutic system containing a pramipexol active agent: The invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 hours....

20060182795 - Compositions containing inclusion complexes: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used...

20060182793 - Cpg-packaged liposomes: Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant...

20060182792 - Liposome-forming compositions: The invention relates to liposome-forming compositions, liposomes produced therewith and the use of said liposome-forming compositions in the production of liposomes....

20060182794 - Stabilized compositions for topical administration and methods of making same: A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as...

20060182796 - Taste masked pharmaceutical compositions: A pharmaceutical composition for oral administration containing a pharmaceutically active ingredient coated with an amount of a polymer combination of an enteric polymer and an ammonio methacrylate copolymer to effectively mask the taste of the medicament. In a preferred embodiment, the ratio of the enteric polymer to the ammonio methacrylate...

20060182798 - Composition for gelatin coating, gelatin coating, and preparation using the same: The present invention relates to a composition for gelatin coating and a gelatin coating characterized by containing a gelatin (A) and an inositol phosphate (B) represented by a general formula: C6H12-n.(H2PO4)n (in the formula, n represents an integer from 1 to 6), and a preparation using the same....

20060182797 - Sutained release formulation for venlafaxine hydrochloride: The invention provides a sustained release composition that; 1. Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. 2....

20060182800 - Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions: The present invention relates to pharmaceutical compositions of antihistamine-decongestant combination. Specifically the invention relates to bilayered tablet formulation comprising antihistaminic decongestant combination. More specifically present invention relates to the novel polymorph of fexofenadine or pharmaceutically accepted salts thereof, with at least one decongestant in the form of bilayered tablet. The...

20060182802 - Rapidly disintegrable solid preparation: A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness....

20060182801 - Sequestered antagonist formulations: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the...

20060182799 - Tabletting process: The invention refers to a process for the preparation of a self-dispersing or self-emulsifying tablet, wherein a heated granulation mixture containing an active lipophilic substance and a surfactant is granulated into granules, said granules are cooled to a semi-solid state, said semi-solid granules are mixed with one or more fillers...

20060182804 - Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods: The present invention also relates to carvedilol free base, salts, anhydrous forms, or solvates thereof, corresponding pharmaceutical compositions or controlled release formulations, and methods delivery of carvedilol forms to the lower gastrointestingal tract or methods to treat cardiovascular diseases, which may include, but are not limited to hypertension, congestive heart...

20060182805 - Dosage form and method for sustained release of substituted pyrazine compound: The invention is directed to a dosage form and method for administering a therapeutic agent in a sustained release manner to provide an intended therapeutic effect while minimizing the side effects associated with the therapeutic agent. The therapeutic agent is selected from a group of substituted pyrazine compounds and may...

20060182803 - Oral sustained-release pharmaceutical composition of indapamide, production and use thereof: The present invention relates to an oral sustained-release pharmaceutical composition of indapamide and a process for producing the foregoing pharmaceutical composition. The pharmaceutical composition comprises indapamide in the amount 0.2% to 4% (w/w) of the composition, a hydrophilic polymer in the amount 10% to 30% (w/w) of the composition, a...

20060182806 - Extended-release propranolol composition: An extended-release pharmaceutical composition comprising a core and a coating, wherein said core comprises propranolol or a pharmaceutically acceptable salt thereof and at least one excipient, and said coating comprises at least one water-soluble polymer and at least one water-insoluble polymer, wherein said coating is heated at a temperature of...

20060182808 - Antisolvent solidification process: The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid...

20060182807 - Copolymer and hemoprotein based novel compounds and uses thereof: The invention relates to novel compounds, characterized in that they comprise a hemoprotein which is associated with a sequenced block copolymer, comprising an hydrophilic segment which is an oligo or polysaccharide linked to at least one hydrophobic segment of formula (1) wherein x represents H or an radical which is...

20060182809 - System for transporting active substances in a biological system: A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles is characterized in that the particles are provided with active substance(s) on at least part of their surface. Modification of the magnetic particles is not absolutely required in this system....

20060182810 - Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release....

20060182811 - Analgesic and anti-inflammatory composition: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of...

20060182812 - Antibacterial compositions and antibacterial products: In the formula, Q denotes at least one type of ion selected from the group consisting of an alkali metal ion, an alkaline earth metal ion, ammonium ion, and hydrogen ion, M is a tetravalent metal ion, n is a number satisfying 0≦n≦6, a and b are both positive numbers,...

20060182813 - Colloidal silver composition having microbial properties: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties....

20060182814 - Biochemically balanced peritoneal dialysis solutions: A peritoneal dialysis solution that is biochemically balanced to correct metabolic acidosis associated with chronic renal failure in a more physiological manner. The peritoneal dialysis solution has a physiological pH, e.g. pH of 70 to 74 and contains bicarbonate at a concentration that is found in normal blood. Additionally, the...

20060182815 - Use of nitrite salts for the treatment of cardiovascular conditions: It has been surprisingly discovered that administration of pharmaceutically-acceptable salts of nitrite is useful in the regulation of the cardiovascular system. It has also been surprisingly discovered that nitrite is reduced to nitric oxide in vivo, and that the nitric oxide produced thereby is an effective vasodilator. These effects surprisingly...

20060182816 - Hypobromous acid system: A system for producing hypobromous acid is provided. An exemplary system includes a carbonic acid source in fluid communication with a chlorinator element for producing a chlorinated carbonic acid solution, a bromine source in fluid communication with the chlorinated carbonic acid solution, wherein the combination of carbonic acid with the...

20060182819 - Soap scent patch and treatment for muscle spasm and pain: A patch and a treatment method for the treatment of human discomforts include transdermal administration of components from soap in the area of discomfort. The patch includes a permeable layer placed against the person, and an impermeable outer cover, and may include tails by which the patch is attached to...

20060182817 - Steroidal sapogenins and their derivatives for treating alzheimer's disease: The invention discloses the use of a number of saponins and sapogenins, notably those of steroidal structure, in the treatment of cognitive disfunction and similar conditions. Methods of treatment, and pharmaceutical compositions are also disclosed....

20060182818 - Transdermal patch and treatment for pain and discomfort: A patch and a treatment method for the treatment of human discomforts includes transdermal administration of components from soap in the area of discomfort. The patch includes a permeable layer placed against the person, and an impermeable outer cover, and may include tails by which the patch is attached to...

20060182820 - Homogeneous dispersions containing citrus pulp and applications thereof: A composition in the form of a homogeneous dispersion that includes citrus pulp and a plant sterol, omega-3-oil, and/or isoprenoid. The dispersion may be incorporated in foods and beverages....

20060182821 - Use of a plant extract: The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine_receptor (PBR) in cells of a patient in need thereof. Further, the...

20060182823 - A process for preparing lotus leaf extracts and method of use: This invention provides a process for extracting the flavonoid and alkaloid components from lotus leaf and provides a method for the reduction of body weight, total cholesterol (TC), low density lipoprotein (LDL) cholesterol, and triglycerides (TG). It also provides a method for increasing high density lipoprotein (HDL) cholesterol and the...

20060182822 - Use of a soluble lucerne extract in order to slow weight gain in mammals: A method uses a soluble Lucerne extract obtained by pressing fresh Lucerne, containing at least 1 wt. % saponines in relation to the weight of the extract, for the production of a food preparation which can limit weight gain in mammals, partially in the case of a hyperlipemic diet, the...

20060182824 - Use of galactomannans as an active cosmetic agent: This invention relates to a method for increasing the adhesion of basal keratinocytes to the Dermoepidermal Junction (DEJ) in a subject, comprising administrating an effective amount of a cosmetic or dermatological composition comprising galactomannans on the skin of the subject, in particular for preventing and/or treating skin aging....

20060182825 - Methods and compounds for the treatment of obesity and obesity-related disorders: In certain embodiments, the invention comprises the use of plant-derived substances to reduce body fat and/or to increase insulin sensitivity in mammals. In certain embodiments, the invention comprises a composition for reducing the amount of fat in the body of a mammal, the composition comprising at least one plant-derived substance...

20060182826 - Extracts of asteraceae containing reduced levels of phototoxic thiophene derivatives and methods for preparing same: The present invention is concerned with extracts of Asteraceae containing reduced levels of phototoxic thiophene derivatives. Novel methods that may result in about a fifty-fold to hundred-fold or more reduction of phototoxic thiophene levels in a commercially attractive process is described. The Asteraceae plant extracts comprising xanthophylls with reduced levels...

20060182827 - Product and process for elevating lipid blood levels in livestock: The present invention provides feed or food products for consumption by animals or humans which include respective quantities of flax oil and non-flax carbohydrate. The flax oil and carbohydrate are mixed together and simultaneously subjected to an elevated temperature of at least about 120° F. and subsequently cooled; the flax...

20060182828 - Methods of reducing lipid peroxidation and achieving related health benefits by the administration of tocopherol and sesame lignans: This invention relates to methods to reduce or lipid peroxidation and diminish free radical damage in a human, resulting in reduced blood levels of dityrosine, isoprostane, and placental growth factor thus preferably preventing or reducing cardiovascular disease by the in humans administration of compositions comprised of sesame lignans and ‘gamma...

20060177373 - Low density radionuclide-containing particulate material: The invention relates to a particulate material consisting of a low density radiation-tolerant glass and a radionuclide incorporated into the low density glass or coated on the low density glass, the glass having a density of less than 2.5 g/cm.sup.3, processes for its production and a method of radiation therapy...

20060177374 - Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments: The present invention relates to a method for treating cancer in an animal by administering to the animal an active vitamin D compound or a mimic thereof in combination with a radiotherapeutic agent or treatment....

20060177375 - Method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect: Generally, the method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect comprises measuring a change in the status of lung infection in a sample population of subjects administered the agent in comparison to a control sample population of subjects; wherein the subjects in the sample...

20060177379 - Composition comprising an agent providing a signal, an implant material and a drug: The present invention relates to compositions or combinations of materials for non-degradable and degradable implantable medical devices with regard to the setup of their signal generating properties and control of their therapeutic effectiveness, as well as to a method for the control of degradation of degradable or partially degradable medical...

20060177377 - Method for monitoring early treatment response: Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor,...

20060177378 - Method for monitoring early treatment response: Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor,...

20060177376 - Stabilized and chemically functionalized nanoparticles: Dendronization of nano-scale surfaces with focal point reactive dendrons to produce stabilized chemically functionalized nano-particles having quantum dot dimensions....

20060177380 - Methods and compositions for deterring abuse of orally administered pharmaceutical products: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended...

20060177381 - Opiopathies: The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture...

20060177382 - Delivery of antiemetics through an inhalation route: The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating...

20060177385 - Compositions for treating dental caries caused by streptococcus mutans infection: A method and pharmaceutical composition for inhibiting infections of S. mutans by the addition of said composition to toothpaste or mouthwash, by inhibiting the production of ADP-glucose, particularly by inhibiting the activity of ADP-glucose pyrophosphorylase or glycogen synthase....

20060177384 - Sialagogue coatings for interproximal devices: Biofilm therapy interproximal devices coated with a sialagogue, a wax/sialagogue, a surfactant/sialagogue, or an emulsion/sialagogue. wherein said devices are suitable for: (c) controlling, disrupting and physically removing biofilms, while (d) increasing and prolonging saliva flow....

20060177383 - Stable tooth whitening gum with reactive ingredients: Oral compositions including an encapsulated active component(s) are provided. The oral compositions include a carrier composition including a first reactive component. The oral compositions also include an active composition. The active composition includes at least one active component encapsulated in a coating. The coating includes a hydrophilic material and at...

20060177387 - Compositions comprising bone marrow cells, demineralized bone matrix and various site-reactive polymers for use in the induction of bone and cartilage formation: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) or demineralized tooth matrix (DTM), together with a site-responsive polymer, optionally further comprising bone morphogenetic proteins (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint or a cranio-facial-maxillary bone,...

20060177386 - Method of regenerating tooth germ and a regenerated tooth germ: An object of the present invention is to provide a method for regenerating tooth germ, and more specifically, to provide a method for regenerating tooth germ that enables the treatment of patients who have lost teeth or have had teeth damaged by dental diseases such as pyorrhea alveolaris or dental...

20060177389 - Natural sunlight photostable composition: The present invention relates to photostable compositions that provide protection from ultraviolet radiation (“UVR”). The invention particularly relates to the sunscreens avobenzone, octocrylene and oxybenzone, forming a triplet combination. Compositions of the present invention are free of diesters or polyesters of naphthalene dicarboxylic acid and also are substantially free of...

20060177392 - Oil-based composition for acne: An oil-based topical composition for use on the skin containing at least one compound from the class of retinoids, which are useful as medicinal agents, in an oleaginous solution composed substantially of non-ionic lipids, which are useful as vehicles for nonpolar compounds....

20060177391 - Preparation, in particular cosmetic preparation, and the production and use thereof: A preparation, in particular a cosmetic preparation, preferably in liquid or pasty form, for use on keratinic materials, in particular for decorating, coloring, improving the appearance of and caring for the skin and the skin appendages. The preparation is water-free and contains at least one wax with a dropping point...

20060177397 - Self-tanning product comprising two components and means for artificially coloring the skin: in which R1, R2, R3 and R4 each independently represent a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R1-R4 representing a hydroxyalkyl group, or salt, solvate, or isomer thereof; the components (A) and...

20060177390 - Skin cancer prevention method and product: The increased use of sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. According to the present invention, the beneficial effects of UV radiation are obtained by incorporating vitamin D into the topical sunscreen. Application of the sunscreen prevents the...

20060177398 - Sunless tanning products and processes: Sunless tanning compositions are substantially improved by adding methylsulfonyl methane [MSM] and certain glycols to Dihydroxyacetone (DHA)....

20060177395 - Sunscreen compositions comprising hydrophilic uv-screening agents and hydroxyalkylurea compounds: in which R1, R2, R3 and R4 each independently represent a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R1-R4 representing a hydroxyalkyl group, or salt, solvate or isomer thereof, formulated into (c) a...

20060177394 - Sunscreen compositions comprising insoluble organic uv-screening agents and hydroxyalkylurea compounds: in which R1, R2, R3 and R4 each independently represent a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R1-R4 representing a hydroxyalkyl group, or salt, solvate or isomer thereof, formulated into (c) a...

20060177393 - Sunscreen compositions comprising lipophilic uv-screening agents and hydroxyalkylurea compounds: in which R1, R2, R3 and R4 each independently represent a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R1-R4 representing a hydroxyalkyl group, or salt, solvate or isomer thereof, formulated into (c) a...

20060177396 - Sunscreen compositions comprising metal oxide mineral pigments and hydroxyalkylurea compounds: in which R1, R2, R3 and R4 each independently represent a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R1—R4 representing a hydroxyalkyl group, or salt, solvate or isomer thereof, formulated into (c) a...

20060177388 - Tanning aids with a high protection factor:

20060177399 - Pressurized device for hair fiber styling and use of the same for hair fiber styling and/or hair: The present invention relates to a pressurized device for hair fiber styling and to its use for hair fiber styling and/or care. The pressurized device, especially an aerosol, comprises a container, the wall of which is made at least partly of a mixture comprising at least one polyethylene naphthalate and...

20060177401 - Fine-texture cosmetic composition: The present invention relates to a pulverulent cosmetic composition, comprising, in a physiologically acceptable medium, an amount effective as binder of at least one short ester and of at least one silicone derivative, wherein: the mass content of short ester(s) is greater than the mass content of silicone derivative(s); and/or...

20060177400 - Topical formulation for the treatment of urushiol induced contact dermatitis and method for treating the same: wherein R1-4 are the same or different and comprise H, a hydroxy group, a straight or branched alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkenyl, alkynyl group containing approximately 1 to approximately 50 carbon atom(s), a silyl or siloxyl group containing approximately 1 to approximately 50 silicon atom(s), and...

20060177402 - Synthetic tear fluid: Synthetic tear fluid comprising at least one glycerophospholipids selected from the group consisting of phosphatidylcholines, phosphatidylserines, phosphatidylethanolamines, and phosphatidylinositol, cholesterol in a glycerophospholipid:cholesterol molar ratio up to 1:1 at least one lipophilic ionic compound, preferably a ganglioside, in a glycerophospholipid:lipophilic ionic compound molar ratio of 100:1 to 10:1 at least...

20060177403 - Synthetic tear fluid: Topically applicable cosmetic/dermatological compositions suited for improving the condition of human keratin fibers, notably human hair, especially for reducing or stopping loss and/or inducing and/or stimulating growth and/or density thereof, contain a thus effective amount of (a) at least one derivative of glucose and of vitamin F, solubilized in a...

20060177404 - Cosmetic composition comprising at least one non-associative fixing polyurethane and at least one sulfonated polymer cosmetic hair treatment process: The present disclosure relates to a cosmetic hair treatment composition comprising at least one non-associative fixing polyurethane and at least one partially or totally neutralized or non-neutralized sulfonated polymer, comprising at least one unit derived from an ethylenically unsaturated monomer containing a non-aromatic sulfonic group....

20060177405 - Moisturizing compositions: A moisturizing composition includes water, a phospholipid, a humectant, and an emollient. The emollient is a fatty ester that has the formula R1—COO—R, wherein R is from an alkyl moiety or a polyol moiety, R1 is from an acyl moiety of a mono- or di-carboxy fatty acid, and R and...

20060177406 - Formula, a system and a method for treating urushiol induced contact dermatitis: A formula, a system and a method is provided for treating urushiol induced contact dermatitis, chemical irritants and/or microbiological irritants on an affected area of skin of a user. The formula and/or the system is applied to an area of the skin of the user affected with urushiol, the chemical...

20060177407 - Antiwrinkle composition and age reversal complex: An alkaline anti-wrinkling composition comprising carnosine, derivative thereof, or mixture of carnosine, and derivative thereof....

20060177408 - Skin external agents and drugs:

20060177410 - Cosmetic compositions and container therefor: A self-standing container holds particles of a cosmetic composition. The container may be cup-shaped or box-shaped, for example, and made of laminated paper or polystyrene. When ready to use, the user opens the container and adds liquid or gel to mix with the dry particles to form a moist cosmetic...

20060177411 - Cosmetic compositions and container therefor: A self-standing container holds particles of a cosmetic composition. The container may be cup-shaped or box-shaped, for example, and made of laminated paper or polystyrene. When ready to use, the user opens the container and adds liquid or gel to mix with the dry particles to form a moist cosmetic...

20060177409 - New cosmetic or dermatological use of ligans: The invention is related to the necessities of life, especially to cosmetology, pharmacology and, more specifically, to dermatology. This invention is the specific subject of a new use of lignans for making cosmetic, pharmaceutical and especially dermatological compounds, used to reduce sebum secretion through topical application. The invention also involves...

20060177412 - Deodorizer: A placement type deodorizer contains a malodor removing material, wherein the deodorizer has Malodor Accessibility Factor (MAF) of more than about 5×104 ppm2 m2/(g*min) and wherein the malodor removing material comprises a malodor removing active....

20060177414 - Pharmaceutical preparations for oral adminstration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents: The present invention relates to pharmaceutical preparations for oral administration, comprising one or more active substances bound to an ion exchanger. In order to improve physical stability and acceptance, particularly in animals, a pseudoplastic gel-former thickener is included....

20060177415 - Once a day formulation for phosphate binders: A method for reducing serum phosphate in a subject in need thereof comprising administering once per day to said subject a phosphate binder, wherein the phosphate binder has a phosphate binding capacity of at least 52 mmole....

20060177416 - Polymer particle delivery compositions and methods of use: The present invention provides biodegradable polymer particle delivery compositions based on polymers, such as polyester amide (PEA) and polyester urethane (PEUR) polymers, that contain amino acids in the polymer. The polymer particle delivery compositions can be formulated as a liquid dispersion of polymer particles with the bioactive agents dispersed in...

20060177413 - Carbohydrate modifiers of neuronal growth: Fucose galactose carbohydrates have been shown to induce neuronal outgrowth. The invention includes methods of inducing neuronal outgrowth using carbohydrates, assemblies, and polymers bearing fucose-galactose moieties, as well as associated proteins. Cell growth can be stimulated in cells in culture or in cells within an animal or patient. Growth stimulation...

20060177418 - Methods for accelerating wound healing by administration of adipokines: Methods for inducing or accelerating a healing process of a damaged skin or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or...

20060177417 - Pharmaceutical formulations for sustained drug delivery: The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides....

20060177419 - Stimulating neutrophil function to treat inflammatory bowel disease: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without....

20060177422 - Method for preparing a physiologically active il-18 polypeptide: The present invention provides a method for producing physiologically active human Interleukin-18 (“IL-18”)....

20060177421 - Treatment of allergic conditions by use of il 21: The invention relates to the administration of IL-21 for management, treatment and prevention of diseases or conditions where eosinophils are involved in a protective response e.g. allergic reactions, allergic diseases, allergic conditions and parasites diseases....

20060177420 - Use of dendritic cells (dcs) expressing interleukin 12 (il-12): The present invention discloses the use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific pathogen or a specific tumor and, due to the treatment with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), release IL-12, for the preparation of a medicament for treating...

20060177423 - Composition and method for killing of tumours: The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps (i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and (ii) administering a prodrug to the subject, wherein the engineered ovine atadenovirus comprises a promoter and...

20060177428 - Vascular endothelial growth factor d (vegf-d) antibodies and vectors, and methods of use: Isolated nucleic acid molecule comprising an antisense nucleic acid sequence which is antisense to a polynucleotide that encodes a VEGF-D polypeptide, vectors and host cells including the same. Also disclosed are methods of inhibiting VEGF-D function or expression in a mammal, for example, in treating cancer, comprising administering to the...

20060177425 - Method for producing working reagent and for biological prevention or control: The present invention provides a method for producing an agent to be used in biocontrol and for preventing plants from suffering from disease. The method includes providing an agent having a microorganism object therein, making the agent contact an external object, and releasing the microorganism object from the agent to...

20060177424 - Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions: A method for treatment or prophylaxis of a disease state or other physiological condition, e.g., autism, delayed development, acid reflux disease, vaginal yeast infections, impaired hearing, chronic ear infections, seasonal allergies, Fibromyalgia syndrome, Crohn's disease, colitis, irritable bowel syndrome, interstitial cystitis, acne, sinusitis, rheumatoid arthritis, chronic fatigue syndrome, asthma, attention...

20060177429 - Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation, systems and compositions: The present invention describes compositions and methods for inhibiting microbial infections associated with the use of sanitary products, such as diapers, bandages, sanitary napkins, tampons, and the like. The present invention comprises providing for use a sanitary product containing an effective amount of a viable, non-pathogenic, lactic acid-producing bacteria, such...

20060177427 - Dna coding for endo-beta-galactosidase: A full-length cDNA is obtained by analyzing the partial amino acid sequence of purified endo-β-galactosidase C, constructing primers based thereon, effecting PCR with the use of the genomic DNA of Clostridium perfringens as a template to thereby obtain a fragment of cDNA encoding endo-β-galactosidase, effecting cassette PCR by using the...

20060177426 - Method of preserving lyophilized microorganisms for transport, storage and recovery of viable microorganisms: Incorporation of a microbial cell suspension throughout a fibrous network provides a physical environment that allows greater removal of water during lyophilization or desiccation thereby yielding a device with improved stability and recovery of viable microbial cells. Strands of appropriate fibers in a tightly knit network absorb aqueous cell suspensions...

20060177430 - Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer: An ophthalmic formulation is provided for the prevention and treatment of adverse ocular conditions, including presbyopia, arcus senilis, age-related macular degeneration, and other conditions associated with aging. The formulation is also useful in the prevention and treatment of other adverse ocular conditions such as those associated with oxidative and/or free...

20060177431 - Inhibitors for continuous activation of calcineurin: The object of the present invention is to provide a suppressant for neuronal cell death effective for various diseases which inhibits a constitutive active forming of calcineurin and has less side effect. An inhibitor of constitutive active forming of calcineurin, more specifically a drug which inhibits cleavage of calcineurin subunit...

20060177432 - Methods and reagents for protease inhibition: The invention discloses a protease inhibitor and a method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of a member of the phosphoethanolamine binding protein (PEBP) family....

20060177433 - Treatment of alpha-galactosidase a deficiency: The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included....

20060177434 - Reduction of adipose tissue: A simple search was made on the Internet. There were at least a few hundred entries. The following seem to be the best of the few dozen examined. The first page of each is cited below for identification....

20060177437 - Binding peptides: methods for their generation and use: Described are means and methods for generating binding peptide associated with a suitable core region, the resulting proteinaceous molecule and uses thereof. The invention provides a solution to the problems associated with the use of binding molecules over their entire range of use. Binding molecules can be designed to accommodate...

20060177435 - Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein b ratios: The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are...

20060177436 - Methods for treating autoimmune disorders: The present invention relates to methods for treating autoimmune disorders. In an embodiment, the invention is directed to a method for treating an autoimmune disorder comprising administering a TCCR agonist. In an embodiment, the autoimmune disorder is at least partially mediated by a Th1 response. In an embodiment, the autoimmune...

20060177441 - Agonist antibodies: Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia....

20060177440 - Compositions and methods for detection of antibody binding to cells: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included....

20060177439 - Fcgammariib-specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention...

20060177438 - Methods of altering absorption of hydrophobic compounds: This invention presents methods of increasing intestinal motility rates in order to decrease intestinal absorption of cholesterol. Furthermore, this invention presents methods of modulating intestinal motility in order to influence positively the amount of drug or nutrient absorption from the intestine, especially of hydrophobic drugs or nutrients. The instant methods...

20060177443 - Integrin antagonists: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration, and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are...

20060177442 - Method of treating cd30 positive lymphomas: Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and proteasome inhibitors in combination are disclosed....

20060177447 - Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention...

20060177444 - Concomitant drug as therapeutic agent for inflammatory bowel disease: An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from...

20060177446 - Polypeptides that bind an anti-tissue factor antibody and uses thereof: The present invention relates to antibodies and polypeptides useful in blocking the binding of antibodies to anti-tissue factor, decreasing the activity of the anti-tissue factor antibodies and/or neutralizing the activity of an anti-tissue factor antibody. The present invention also relates to nucleic acids encoding the antibodies and polypeptides and compositions...

20060177445 - Treatment of inflammatory skin diseases: The present invention includes methods for the treatment of rosacea and seborrhea comprising the administration of inhibitors of gamma interferon and tumor necrosis alpha and the administration of antibiotics, alone or in combination....

20060177448 - Inhibiting her2 shedding with matrix metalloprotease antagonists: The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding....

20060177455 - Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of said antibodies, humanized and resurfaced versions of said antibodies, functional equivalents and improved versions of said antibodies, immunoconjugates and compositions comprising said antibodies, and the uses of same in...

20060177453 - Antibodies that bind to epha2 and methods of use thereof: Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed....

20060177449 - Antibody and use thereof: The antibody of the present invention, which is specifically reacting with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc....

20060177456 - Apo-2 receptor antibodies: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided....

20060177451 - Binding molecules for the treatment of myeloid cell malignancies: The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The...

20060177452 - Ephb receptor-binding peptides: The application is related to the identification of peptides that selectively bind to Eph receptors of the B class. Also disclosed are uses of such peptides in the treatment of a variety of diseases. Additionally, imaging tumors in patients is described by administrating labeled peptides to patients and then obtaining...

20060177454 - Method of promoting an immune response with a bispecific antibody: A method of inducing an immune response in a patient is provided. The method involves administration of bispecific molecules capable of recognizing and binding FcγRIII and a second antigen. The second antigen may be a cancer antigen, a viral antigen, a fungal antigen, a bacterial antigen or a toxin. The...

20060177450 - Prostate-specific membrane antigen: This invention provides for an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention provides for nucleic acid probes which specifically hybridize with the nucleic acid molecule encoding said antigen. This invention provides for a method of detecting hematogenous micrometastic tumor cells of a subject performing...

20060177457 - Dye-sulfenates for dual phototherapy: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are...

20060177458 - Compositions of cpg and saponin adjuvants and uses thereof: Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same....

20060177459 - Treatment and diagnosis of infertitlity using tgfbeta or activin: A method of treating an infertility condition in humans or mammals, by exposure of a prospective mother to TGFβ or derivative or analog of TGFβ. The exposure is advantageously in conjunction with one or more antigens of a prospective father so that a hyporesponsive immune reaction is mounted to the...

20060177460 - Stress proteins and uses therefor: The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results...

20060177461 - Stress proteins and uses therefor: The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results...

20060177463 - Compositions and methods for inhibiting h. pylori adhesion and infection: The present invention provides compositions and methods for treating or preventing bacterial infections. Also provide by the invention are genetically modified cell expressing Lewisb carbohydrate epitope....

20060177464 - Methods and compositions involving lcrv proteins: The present invention concerns methods and compositions involving modified LcrV proteins from Yersinia bacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not suppressing the immune system as much as the native LcrV protein. In certain embodiments, the present...

20060177466 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections: Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their...

20060177462 - Polypeptides for inducing a protective immune response against staphylococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length <i>S. aureus</i> polypeptide. The full-length polypeptide is referred to herein...

20060177465 - Streptococcus antigens: Streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection....

20060177467 - Use of incense or hydrogenation products for preventing and/or treating a cerebral ischemia and/or cerebral traumatic lesion: The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The...

20060177468 - Delivery vehicles, bioactive substances and viral vaccines: The invention relates to compositions and methods for the safe delivery of a bioactive agent to an animal. Preferably, the bioactive agent is a vaccine, and more preferably, the bioactive agent is a virus....

20060177469 - Non-toxic mucosal adjuvant: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions....

20060177470 - Dna sequence and recombinant production of the grass pollen allergen phl p4: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial...

20060177471 - Topical personal care compositions and methods of use: Topical personal care compositions comprising an anti-inflammatory agent, an amphoteric surfactant, a bodifier/humectant, and water and methods of use are disclosed....

20060177473 - Head lice medication and treatment: The medication for head lice includes glue and a de-licing insecticide such as d-Limonene or highly concentrated lemon juice. The glue is effective because application of the glue, in a soft or liquid state, to the hair and scalp results in the lice becoming entrapped in the glue. When the...

20060177472 - Insect repellent coating and industrial product using the same: A pest repellent paint contains at least one extract selected from the group consisting of an extract of a whole plant which belongs to a wintergreen family (Pyrolaceae), an extract of a whole plant which belongs to a nasturtium family (Tropaaeolaceae), an extract of branches and leaves of a plant...

20060177474 - Agricultural and horticultural poison bait preparation: (wherein R1 is a (C1-C6)alkyl group, a (C1-C6)alkylthio(C1-C6)alkyl group, a (C1-C6)alkylsulfinyl(C1-C6)alkyl group or a (C1-C6)alkylsulfonyl(C1-C6)alkyl group; each of Xs, which may be the same or different, is a halogen atom; n is 1 or 2; each of Ys, which may be the same or different, is a halogen atom, a...

20060177475 - Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but...

20060177477 - Catheter lock solution comprising citrate and a paraben: This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention...

20060177478 - Intravascular blood conditioning device and use thereof: Disclosed is an implantable, intravascular device for treating a medical disorder associated with the presence of a particular molecule in the systemic circulation of a mammal. When implanted, the device removes or reduces the concentration of the molecule in the blood stream thereby conditioning the blood. The device includes an...

20060177476 - Medical devices and methods for modulation of physiology using device-based surface chemistry: This invention provides implantable medical devices having at least one moiety attached to the surface capable of catalyzing a reaction in vivo. The implantable medical device has a body such as a stent with a surface adapted to be placed adjacent to a biological tissue or fluid. The body has...

20060177480 - Drug-eluting biodegradable stent: The present invention relates to a biodegradable stent comprising a luminal surface portion with a second degree of crosslink, an outer surface portion with a first degree of crosslink, and a wall between the luminal and outer surface portions, wherein the wall comprises a crosslinked material characterized by the first...

20060177479 - Methods and devices for promoting epithelial cell differentiation and keratinization: In one aspect, the present invention provides a biomaterial having at least one biocompatible surface. The biocompatible surface comprises a plurality of immobilized Notch ligand molecules, wherein the plurality of immobilized Notch ligand molecules are capable of promoting differentiation in one or more epithelial cells. In another aspect, the present...

20060177481 - Methods for forming regional tissue adherent barriers and drug delivery systems: Methods are provided for forming hydrogel barriers in situ that adhere to tissue and prevent the formation of post-surgical adhesions or deliver drugs or other therapeutic agents to a body cavity. The hydrogels are crosslinked, resorb or degrade over a period of time, and may be formed by free radical...

20060177482 - Stent with coatings containing self-assembled monolayers: A medical device with a coating, particularly a drug eluting stent, is described. The coating includes a self-assembled monolayer....

20060177483 - Contact drug delivery system: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having coamplexing...

20060177485 - Animal feed composition for increased production of glutathione peroxidase and superoxide dismutase: A food composition for consumption by mammals is designed to increase the production of glutathione peroxidase and superoxide dismutase. A serving of the food composition has a total weight and includes, in order of decreasing weight, a meat, a brassica vegetable, and brown rice....

20060177484 - Cheese alternative product and process for preparing a cheese alternative product: A cheese alternative product is prepared from filled milk formed from dairy origin skimmed milk and vegetable oil. The vegetable contains blood cholesterol lowering agent in an amount such that in the product the blood cholesterol lowering agent has a blood cholesterol level lowering effect. The blood cholesterol lowering agent...

20060177486 - Enzymatically synthesized marine phospholipids: This invention discloses an improved enzymatic process, under organic solvent free conditions, for the incorporation of fatty acids such as omega-3 fatty acids into phospholipids. The rate of transesterification is increased 4 times by adding a base to the reaction mixture, typically an amine. The invention also discloses novel phospholipid...

20060177488 - Abrasive wipe for treating a surface: The present invention relates to a pre-moistened wipe for treating a surface, said pre-moistened wipe comprising: (a) a substrate having a plurality of abrasive means applied thereon, wherein the material forming the abrasive means has a Vickers hardness HV of at least 3 kg/mm2 and wherein said abrasive means is...

20060177489 - Attachment of chitosan to surfaces using rehydration process: A method for attaching chitosan to the surface of polymers that includes at least one rehydration step has been developed to provide more effective and stable chitosan coating. Polymers produced using this method and articles that are made with these polymers provide antibacterial and anti-odor properties....

20060177490 - Chitosan-base antimicrobial thermoplastic polymer blends: A method is provided to produce antimicrobial thermoplastic polymer blends by blending chitosan acid salts with polymers having amino-reactive functional groups. The antimicrobial thermoplastic polymer blends produced and articles composed of these materials are described....

20060177487 - Moisture and lotion retainer: An occlusive retainer article to maintain user manually applied cosmetics, such as lotions, creams, and/or oils on human and animal skin in desired locations....

20060177491 - Oil soft gel sheet for application to skin: The present invention relates to an oil soft gel sheet for application to the skin, which can be suitably used to allow an active ingredient to be absorbed into the skin or the human body through the skin. The oil soft gel sheet is in the form of a monolayer...

20060177492 - Collagen gel and process of producing the same: The present invention relates to a process of producing a collagen gel comprising collagen fibers cross-linked with each other by a cross-linking agent on the way of fibrosis of collagen, and a collagen gel comprising the cross-linked collagen fibers obtained by the process. The collagen gel comprising cross-linked collagen fibers...

20060177494 - Coated microprojections having reduced variability and method for producing same: The present invention provides methods and devices for reducing the coating variability of a transdermal microprojection delivery device. The device has one or more stratum corneum-piercing microprojections, wherein each microprojection has a maximum width located in the range of approximately 25% to 75% of the length of the microprojection and...

20060177493 - Transdermal granisetron: Adhesive patches for the transdermal administration of granisetron, comprise an acrylic adhesive containing non-acidic nucleophilic moieties which substantially increase flux of granisetron across the skin....

20060177495 - Polymer-lipid delivery vehicles: Delivery vehicles comprising nanoparticles which are composed of: (a) a biodegradable hydrophobic polymer forming a core, and; (b) an outer amphiphilic layer surrounding the polymer core containing a stabilizing lipid are suitable for delivering active agents....

20060177497 - Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention: A controlled-release dosage form is described, which comprises a matrix formed of ingredients (a) and (b): (a) gellan gum, and (b) one or more hydrophilic polymers; and further comprising a drug incorporated within said matrix. The invention also describes a method for the preparation of said controlled-release dosage forms....

20060177496 - Pharmaceutical formulations: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units...

20060177503 - Bambuterol and integrin inhibitor combination and treatment method: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of bambuterol, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms...

20060177504 - Combination pain medication: This patent is an evolution of previous combination medication patents. Previous combination patents such as U.S. Pat. No. 6,613,354 which is a combination of an NSAID and Proton Pump Inhibitor. Thus the previous patents have covered gastrointestinal prophylaxis but none has covered both gastrointestinal and cardiovascular prophylaxis. This is likely...

20060177501 - Film coated tablets containing ibuprofen: The invention relates to film-coated tablets containing ibuprofen lysinate with improved stability, bioavailability and higher acceptance (compliance) in patients, and the use of these film-coated tablets for preparing a pharmaceutical composition for the treatment of acute and/or chronic pain....

20060177499 - Method for the manufacture of a pharmaceutical composition in the form of tablets containing a fibrate and tablets obtained according to the method: A method for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, optionally in combination with a second active ingredient, in the form of tablets, characterized in that it comprises a compression step of the active ingredient and excipients by means of a...

20060177500 - Solid dispersion of tacrolimus: The present invention relates to the carrier of the solid dispersion of tacrolimus, which is prepared by using the solid surfactant having a property of HLB value higher than or equal to about 7. The surfactants carry out a function of a carrier and a function of a dissolution enhancer,...

20060177498 - Solid pharmaceutical composition comprising ramipril: The present invention relates to solid pharmaceutical compositions comprising ramipril with a suitably low water content, and processes for preparing said compositions....

20060177502 - Sustained release pharmaceutical formulations: Disclosed are novel ranolazine sustained release pharmaceutical formulations....

20060177505 - Cleaning composition in solid form: Cleansing composition provided in solid form and containing, in an anhydrous medium, at least one active agent chosen from salicylic acid and its derivatives, at least one pulverulent foaming surfactant, and at least one water-soluble polymer, it being possible for the quantity of water-soluble polymer to be up to 10%...

20060177507 - Controlled release device containing lercanidipine: The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways...

20060177506 - Release control compositions: wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing...

20060177508 - Fast disintegrating tablet: The invention concerns an improved multiparticulate tablet disintegrating in the mouth in contact with saliva in less than 40 seconds. The invention is characterised in that it is based on particles of coated active principle, said particles having intrinsic compression properties and a mixture of carriers, the proportion of carrier...

20060177509 - Controlled release composition: The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains 1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate, 2) a...

20060177510 - Dual controlled release osmotic device: A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or...

20060177511 - Antiseptic compositions and methods: Antiseptic compositions, as well as methods of making and using, wherein the compositions include: an antimicrobial agent selected from the group consisting of iodine (I2), an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient to provide an available iodine concentration of at least...

20060177513 - Embolization using poly-4-hydroxybutyrate particles: Absorbable particles which comprises poly-4-hydroxybutyrate and/or its copolymers are formulated in injectable suspension suitable for prophylactic or therapeutic embolization, which comprises administering to a human or animal the injectable suspension process for producing particles of the poly-4-hydroxybutyrate and/or its copolymer....

20060177512 - Process for preparing formulations of lipid-regulating drugs: A process for preparing a formulation of a lipid-regulating drug comprising dissolving said lipid-regulating drug in a solvent free of surfactant, premixing an excipient, wet granulating the drug solution/excipient mixture, drying the mixture and forming a final dosage form....

20060177514 - Preparation of a therapeutic composition: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum...

20060177515 - Method of producing autogenous or allogenic blood serum and related logistics: A method of producing blood serum containing prophylactically or therapeutically active proteins, including obtaining blood from a patient, incubating the blood at a suitable temperature to induce production of prophylactically or therapeutically active proteins, and removing the prophylactically or therapeutically active proteins from the blood....

20060177516 - Food-supplement composition suitable for promoting iron absorption: Use of a composition comprising cartilage or chondroitin sulphate and absorbable zinc for the preparation of a food supplement or a drug suitable for promoting iron absorption in patients suffering from lack of iron....

20060177517 - Antiinflammtory agent and antiinflammatory medical material: An object of the present invention is to provide an anti-inflammatory agent and an anti-inflammatory medical material, which have a good anti-inflammatory effect and high safety. The present invention relates to an anti-inflammatory agent and an anti-inflammatory medical material, which contain as an active ingredient a polyphosphoric acid that is...

20060177518 - Peracetic teat dip: A teat dip formula is disclosed for use on dairy animals with the objective of reducing or preventing mastitis. The teat dip formula preferably includes up to about 5000 ppm of peracetic acid in solution made in situ by mixing acetic acid and hydrogen peroxide. Other constituents of the formula...

20060177519 - Chemotherapeutic agents for the control of plant and animal diseases: A chemotherapeutic composition for the control of plant diseases caused by viral, bacterial, and fungal organisms is disclosed. The composition is composed essentially of a tannate complex of cupric ammonium formate in aqueous solution combined with a an amount of a surfactant sufficient to prevent separation of ammonium tannate. The...

20060177520 - Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis: Compositions and methods for reducing cytotoxicity are provided. Compositions and methods for inhibiting angiogenesis are provided. The compositions comprise herbals, natural nutritional supplements, minerals and/or vitamins....

20060177521 - Humidifer sanitization: A humidifier that delivers dilute hypohalous acid can effectively treat microganisms in the room while at the same time raising the humidity level. This humidifier system can be used to treat mold, microorganisms, and allergens, while being safe to use around people, pets, and food....

20060177522 - Rinsing solution for contact lenses: The invention relates to the use of an aqueous ionic solution for rinsing contact lenses, particularly contact lenses made of hydrophilic materials. Said aqueous ionic solution is produced from sea water, has an ionic composition that is of the same quality as that of sea water, and the quality of...

20060177523 - Administration of a thiol-based chemoprotectant compound: A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or...

20060177524 - Ocular irrigating solution: A disclosed ocular irrigating solution for irrigating the eye during surgery comprises a source of bicarbonate ions and a physiologically acceptable organic buffer which is an organic zwitterionic buffer having a buffering capacity with in the range pH 6.8 to 8.0....

20060177526 - Pharmaceutical preparation: The present invention provides for a method of treating eczema by administering a pharmaceutical preparation comprising active substances from each of Centella asiatica, Mohonia aquifolium and Viola tricolor....

20060177525 - Process for producing proanthocyanin-rich material: The method comprises the process of treating an extract or squeezed juice of a plant with a salt and/or an alkaloid and then with a synthetic resin adsorbent, or the process of treating an extract or squeezed juice of a plant with a synthetic resin adsorbent and then with a...

20060177527 - Methods and compositions for treating psoriasis: A topical composition for treating psoriasis, comprising bee honey, Boswellia resin and willow tissue or an extract thereof and a method of using same in therapy....

20060177528 - Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting...

20060177529 - Aleurone product and corresponding production method: The invention relates to an aleurone product comprising particles originating from the aleurone cells (of cereal, in particular the aleurone cells of wheat. The invention is characterised in that the particles originating from the cereal aleurone cells are finely ground with a diameter of up to 500 μm as the...

20060177530 - Method of treating diabetes type ii: A method of treating early diabetic neuropathy includes administering a composition comprising an aqueous extract of olives is disclosed. A method of treating patients with Cfiber neuropathy includes administering a composition comprising an aqueous extract of olives. A method of treating patients with large fiber and C-fiber neuropathy includes administering...

20060177531 - Compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments...

20060171881 - Compounds with high monoamine transporter affinity: Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking...

20060171882 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled compounds by thermally induced free radical carbonylation: Methods and reagents for thermally initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with nucleophiles are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided....

20060171884 - Binding proteins specific for human matriptase: Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses...

20060171883 - Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope: A Disclosed are methods for detecting and localizing a cell-specific antigen in a mammal, such as a human subject, comprising exposing peripheral blood mononuclear cells (PBMCs) of the mammal to an immunogenic peptide epitope of the antigen, under conditions for antigen-specific activation of T lymphocytes in the PBMCs, thereby producing...

20060171885 - Skin or hair binding peptides: The invention is directed to peptides. Specifically, the invention is directed to peptides which bind skin and do not bind hair. Alternatively, the invention is drawn to peptides which bind hair and do not bind skin....

20060171889 - Irrigating fluid: A surgical irrigating fluid composition, especially for endoscopic surgery, is provided comprising a rinsing fluid and nitrous oxide added as a marker to the rinsing fluid in an amount which is detectable in the expired breath from a mammal, especially man, that is subjected to the surgery....

20060171888 - Medical device and method for diagnostic sensing: Devices are provided for use in medical diagnostics which include a substrate, a plurality of discrete reservoirs located in the substrate, each reservoir having at least one opening, at least one diagnostic substance contained in each reservoir, and at least one non-degradable barrier layer covering each reservoir opening, the barrier...

20060171886 - Method for characterizing the oxidative stress protective capacity of an antioxidative substance: A method for characterizing an oxidative stress protective capacity of an antioxidative substance includes assigning a first score indicative of an oxidative stress protective capacity of a first antioxidative substance. The first score is based on the performance of the first antioxidative substance in a first antioxidative efficacy test relative...

20060171887 - Method for the diagnosis of helicobacter pylori infection and diagnostic kit for performing the method: The method for the diagnosis of Helicobacter pylori infection by the oral administration of defined amounts of 13C-labeled urea together with a sufficient amount of an acid bringing down the pH of the solution and thereafter examining the 13C content in the urea breast test (13C-UBT), is improved in that...

20060171890 - Methods for evaluating the activity of candidate agents: Methods for evaluating the activity of candidate agents are provided. In practicing the subject methods, a candidate agent is administered to an injured tissue site of an animal and the activity of the candidate agent on the injured tissue site is evaluated. Also provided are kits and systems for use...

20060171892 - Conjugates for medical imaging comprising carrier, targetting moiety and a contrast agent: This invention relates to the delivery of agents to the body. One particular class of such agents are contrast agents useful in medical imaging techniques. The agents may be metals useful as contrast agents in magnetic resonance imaging (MRI), or in nuclear imaging, including positron emission tomography (PET), or as...

20060171891 - Nmr-based methods for detecting ligands, where the ligand or target are hyperpolarized and the nmr-spectrum is compared with a reference spectrum of the ligand or target: The invention relates to NMR-based methods comprising hyperpolarised ligands or targets for use in NMR-based assays....

20060171894 - Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system: e

20060171895 - Medical imaging reference devices: A medical device can be placed within or on the body of a patient. The device can include one or more imaging agents to allow visualization of the location of the device by an imaging system such as an MRI, an ultrasound, a PET, a CT, or an IR imaging...

20060171893 - Antineoplastic agents targeted via glut transporters: The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neo-plastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker...

20060171896 - Buccal, polar and non-polar spray containing alprazolam: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide alprazolam for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, alprazolam, and optional flavoring agent; formulation II:...

20060171898 - Corticosteroid-containing pharmaceutical composition: The present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and surface active agent. The compositions of the invention can be used to treat...

20060171897 - Methods and formulations for the efficient delivery of drugs by nebulizer: Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs and drugs requiring storage in aqueous or other water-miscible pharmaceutically unacceptable vehicles for stability are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of...

20060171899 - Water-stabilized aerosol formulation system and method of making: The invention relates to an aerosol formulation system comprising a primary package system and an aerosol formulation therein wherein the aerosol formulation comprises insulin, a propellant and an amount of water sufficient to reach equilibrium quantities based on the moisture sorption rate diffusing across the primary package system in which...

20060171900 - Polyether-based composition curable by metathesis reaction: One-part and two-part compositions curable by a metathesis reaction comprising a resin containing a polyether-based substrate with at least two cycloolefin groups per molecule curable by a metathesis reaction with a metathesis catalyst. These compositions may optionally contain a reaction control agent for slowing the progress of the metathesis reaction....

20060171902 - Engineered oral tissue structural constructs: The invention is directed to compositions and methods for preparing an artificial oral tissue. The artificial oral tissue is prepared using a biocompatible substrate seeded with salivary gland cells that develop to produce a salivary gland tissue layer with a prototypal salivary system and a prototypal secretory system. The salivary...

20060171901 - Treatment of malodour: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis....

20060171904 - Enhanced anti-carious dentifrices, rinses, lozenges, candies and chewing gums and methods of using same: Mouth rinses, dentifrices, lozenges, confections, chewing gums, and similar delivery vehicles containing non-toxic soluble calcium are used prior to administration of a fluoride-containing composition to increase the effectiveness of the fluoride therapy. An effective amount of calcium is released into the oral cavity and allowed to penetrate into the oral...

20060171903 - Oral cavity composition: The present invention provides an oral cavity composition with which brief treatment using the same yields a high effect for dental cavity prevention and an excellent dental hyperesthesia preventive and treatment effects, and a method of treatment using such a composition. The oral cavity composition according to the present invention...

20060171905 - Dental bleaching compositions having a protective coating applied thereto: A dental bleaching material comprises a dental bleaching composition that includes a dental bleaching agent and a thickening agent and a protective coating on a surface of the dental bleaching composition that includes a complex of polyvinyl pyrrolidone (PVP) and hydrogen peroxide (H2O2). The bleaching composition may be a gel...

20060171907 - Oral care compositions providing enhanced whitening and stain prevention: The present invention relates to oral care compositions containing an agent having substantivity to teeth, in particular polyphosphorylated compounds having at least 3 phosphate groups such as linear condensed polyphosphate polymers and phytate, which in combination with a tooth bleaching agent such as peroxide provide enhanced whitening and stain prevention...

20060171906 - Sustained release tooth whitening formulations and systems: A new tooth whitening composition provides sustained release of high levels of whitening agent and is moisture-activated without significant swelling. A preferred system for applying the composition to the teeth is flexible, self-adhesive, and well-tolerated by users. In certain embodiments the tooth whitening composition comprises a mixture of tooth whitening...

20060171908 - Pressure-sensitive adhesive composition applicable to nail and adhesive agent for nail: The present invention aims at providing a pressure-sensitive adhesive composition applicable to nail, which shows superior adhesive performance (adhesive force, cohesion etc.), and superior drug releasability and drug stability, and an adhesive agent for nail, which uses this composition. The composition of the present invention contains a condensation polymer of...

20060171909 - Cosmetic compositions comprising colorants with low free dye: Cosmetic compositions suitable for changing the appearance of keratinaceous substances, such as mammalian skin, hair, and nails. The compositions comprise an encapsulated colorant having a high encapsulation efficiency, which mitigates colorant staining of the keratinaceous substance, and a particle size that yields the desired color....

20060171910 - Cosmetic composition containing an alkoxylated alcohol ester and a hydrocarbon-based ester oil: The present disclosure relates to a composition comprising at least one ester of an alkoxylated alcohol and a carboxylic acid and at least one ester oil different from the preceding ester, the composition being capable of forming a deposit with a staying power index of greater than or equal to...

20060171912 - Diiodomethyl-p-tolylsulfone as a particulate dispersion in a liquid solvent: The present invention relates to a composition comprising an effective amount of diiodomethyl-p-tolylsulfone wherein the diiodomethyl-p-tolylsulfone is present as a particulate dispersion in a liquid solvent. In a further embodiment, the present invention relates to a composition wherein at least about 30% retained activity is achieved as the diiodomethyl-p-tolylsulfone is...

20060171911 - Diiodomethyl-p-tolylsulfone as a particulate dispersion in a liquid solvent in combination with an anti-dandruff active: The present invention relates to a composition comprising an effective amount of diiodomethyl-p-tolylsulfone wherein the diiodomethyl-p-tolylsulfone is present as a particulate dispersion, an effective amount of a surfactant, and an effective amount of an antidandruff active....

20060171913 - O/w emulsifier and o/w emulsions containing potassium cetyl phosphate and method for the production thereof: O/W emulsifying agents are described, comprising: (a) hardened palm oil glycerides and (b) potassium cetyl phosphate wherein the proportion of potassium cetyl phosphate is in the range from 40 to 80% by weight, based on the total mass of the emulsifying agent. Also described are corresponding O/W emulsions, comprising a...

20060171914 - Botanically derived cleanser: A cleanser is disclosed that includes a cleansing agent derived from a botanical matter. Each cleansing agent of the cleanser is derived from botanical matter. The cleanser also includes at least one aromatic agent derived from botanical matter. Each aromatic agent of the cleanser is derived from botanical matter. The...

20060171916 - Phosphate-binding polymers for oral administration: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia....

20060171915 - Blood coagulation promoter and blood collection tube: The present invention provides a blood coagulation promoter capable of exerting both excellent blood coagulation promoting ability and excellent blood clot detaching ability; and a blood collection tube accommodating the blood coagulation promoter. The present invention provides a blood coagulation promoter which includes a hardly water soluble polyoxyalkylene derivative; a...

20060171918 - Apoptosis inducing molecule i: The invention relates to Apoptosis Inducing Molecule-1 (AIM-I) polypeptides useful in biological, diagnostic, clinical or therapeutic arts....

20060171919 - Targeted polypeptides: The present invention regards targeted BLyS polypeptides capable of binding to BLyS receptors and that deliver a cytotoxic agent, such as a cytotoxic peptide, for example. In particular aspects, the cytotoxic agent comprises at least part of rGelonin. These compositions are useful for treating, preventing, and/or monitoring therapy for a...

20060171917 - Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents: The present invention relates to compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more adjuvants. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one adjuvant, which enhances the immune response to the antigenic or immunogenic agent,...

20060171921 - Glycosylated interferon: This invention includes compositions comprising glycosylated human interferon-α derived from a chicken....

20060171920 - Reversible pegylated drugs: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG...

20060171925 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060171924 - Bidirectional promoters for small rna expression: The invention provides bidirectional promoters for expressing two or more short RNA sequences from a single promoter. A particular embodiment of the bidirectional promoters of the invention include: 1) a Pol III promoter that contains a TATA box, a PSE and a DSE; and 2) a Pol III promoter that...

20060171926 - Gene therapy for neurometabolic disorders: The disclosure pertains to methods for treating neurometabolic disorder including lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector...

20060171922 - Helper virus-free herpesvirus amplicon particles and uses thereof: The invention features new helper virus-free methods for making herpes virus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas)....

20060171927 - Method of inducing neuronal production in the brain and spinal cord: The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain....

20060171923 - Methods of identifying modulators of human retrovirus replication: This invention relates to the discovery that the transcription factors Pbx1 and HMG1 are involved in retrovirus, e.g., HIV, replication. Thus, the invention provides methods of identifying modulators of these proteins. Such modulators can be used as reagents in in vitro assays to modulate expression of retroviral sequences and may...

20060171933 - Cell culture: A method for culturing mammalian cells without the need for the addition of xenobiotic materials which promote mammalian cell culture, for example, serum or a pituitary extract and including methods for the production of cells for use in tissue engineering and the production of recombinant protein....

20060171934 - Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering lymphoid cells such as natural killer (NK) cells...

20060171935 - Protecting cell therapy for neurological disorders including parkinson's disease: The present invention provides compositions and methods for enhancing and improving cell therapies for neurological disorders including Parkinson's disease. Specifically, the present invention provides a cell or cells modified by viral vector compositions that allow for the over-expression and RNAi mediated knockdown of genes in vitro and in vivo. The...

20060171936 - Cosmetic and/or dermatological composition for sensitive skin: The present invention relates to the use of an effective amount of at least one microorganism belonging to the species Lactobacillus paracasei or casei, a fraction thereof or a metabolite thereof, in combination with an effective amount of at least one microorganism belonging to the species Bifidobacterium longum or Bifidobacterium...

20060171932 - Adipose derived stromal cells exhibiting characteristics of endothelial cells: The present invention encompasses an adipose-derived adult stromal (ADAS) cell exhibiting at least one characteristic of a pre-endothelial cell and/or an endothelial cell. The present invention also encompasses compositions and methods for generating an adipose-derived adult stromal to exhibit at least one characteristic of a pre-endothelial cell and/or an endothelial...

20060171931 - Methods and compositions for modulating stem cell growth and differentiation: Compositions and methods for modulating proliferation and/or lineage commitment of stem cells by modulating the Wnt signalling pathways. Modulators of the Wnt signalling pathways and screening methods to identify modulators are also provided. The methods of the invention may be conducted in vitro or in vivo to induce or inhibit...

20060171928 - Monocyte-origin multipotent cell momc: The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone,...

20060171930 - Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described....

20060171929 - Regulation of dendritic cell functions by the dcal-2 receptor: This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer...

20060171937 - Method of treating chronic cardiac disease: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease....

20060171938 - Compositions and methods for enhancing cognitive function: The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus Coffea, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of...

20060171939 - Remedy for degenerative intervertebral discs: To treat diseases accompanied by degenerative intervertebral discs, in particular, disk herniation, lumbar pain, discopathy and osteoarthritits of the spine, it is intended to provide a drug for administering a human-origin protease directly to an affected part of such a disease accompanied by degenerative intervertebral discs. As the human-origin protease,...

20060171940 - Antibody disulfide isomers, use thereof, and methods of analyzing same: The present invention relates to disulfide isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNFα). The present invention also relates to compositions comprising the isomers and therapeutic uses of the antibody. The present invention also relates to analytical methods of detecting the TNFα...

20060171943 - Compositions and methods of treating fibrotic disorders: The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at...

20060171941 - Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain...

20060171942 - Modified fusion molecules for treatment of allergic disease: The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains...

20060171944 - N-formyl peptide receptor mediation of platelet chemotaxis toward injured cells and activation of immune response: The present invention relates to N-formyl peptides that induce an immune response, specifically, stimulating mobilization of platelets to a site of injury, thereby healing wounds. Further, the invention relates to N-formyl peptide receptor inhibitors, specifically N-formyl peptide receptor antibodies, that inhibit an immune response, thereby blocking inflammation and the mobilization...

20060171946 - Compositions and methods for the treatment and prevention of hyperproliferative diseases: Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods....

20060171945 - Ip receptor antagonists for the treatment of pathological uterine conditions: A method of combating a pathological condition of the uterus in a female individual, the method comprising administering to the individual at least one agent that is an antagonist of the IP receptor and/or a PGIS inhibitor. The pathological condition of the uterus is uterine carcinoma, menorrhagia, dysmenorrhoea or an...

20060171948 - Methods of using il-1 antagonists to reduce c-reactive protein: Methods of reducing C-reactive protein (CRP) in a subject, comprising administering to the subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein CRP is reduced. The IL-1 antagonist is preferably an IL-1-binding fusion protein (IL-1 trap), preferably comprising SEQ ID NO:2....

20060171947 - Serine/threonine hydrolase proteins and screening assays: Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of...

20060171951 - Antibodies to oncostatin m receptor: The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta....

20060171949 - Combination cancer immunotherapy with co-stimulatory molecules: Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity...

20060171952 - Jam-3 and antibodies that bind thereto: The invention provides the identification and characterization of disease and cancer-associated antigen, JAM-3. The invention also provides a family of monoclonal antibodies that bind to antigen JAM-3, methods of diagnosing and treating various human cancers and diseases that express JAM-3....

20060171950 - Use of cd23 antagonists for the treatment of neoplastic disorders: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL)....

20060171954 - Antigen specific activated t-lymphocytes, detection and use: The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds....

20060171953 - Tumour-specific animal proteins: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions....

20060171955 - Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv: A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least a 5-fold increase in F and G protein yields when compared with the parent A2...

20060171956 - Sphingoid polyalkylamine conjugates for hepatitis b virus vaccination: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for stimulating or enhancing an immune response of a subject to protect against Hepatitis B...

20060171957 - Polypeptide-vaccines for broad protetion against hypervirulent meningococcal lineages: A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET...

20060171958 - Antiviral activity from medicinal mushrooms: Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis, Piptoporus, Ganoderma and blends of medicinal mushroom species and are useful in preventing and treating viruses including Orthopox viruses, influenza, avian influenza, Venezuelan Equine Encephalitis, yellow fever, West Nile, Dengue,...

20060171959 - Virulence genes, proteins, and their use: A series of genes from Pseudomonas aeruginosa and Klebsiella are shown to encode products that are implicated in virulence. The identification of theses genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used to identify antimicrobial drugs, diagnostic methods for the identification...

20060171960 - Methods and composition for oral vaccination: The present invention encompasses methods and compositions both for providing protection against disease in an animal and for inducing increased intake of an orally administered vaccine by an animal. The methods of the invention are directed to admixing a bacterial or viral antigen with a water soluble palatable flavorant, further...

20060171961 - Composition and method for preventing or treating a virus infection: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections....

20060171962 - Sars vaccine: The present invention is directed to vaccines comprising a virus particle comprising a nucleic acid and one or several coat proteins, wherein (a) the nucleic acid encodes SARS-CoV replicase, SARS-CoV N protein and at least one further SARS-CoV protein; and (b) the one or several coat proteins are SARS-CoV coat...

20060171963 - Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine...

20060171964 - Polypeptides and polynucleotides from coagulase-negative staphylococci: Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG...

20060171965 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and...

20060171966 - Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype: The invention relates to novel types of Vibrio cholerae that are useful for vaccines and immunological compositions....

20060171967 - Means and methods for diagnosing a treponema infection: The present invention relates to a carrier for diagnostics and/or follow-up of a Treponema infection and to a diagnostic method using said carrier. According to the invention a carrier is provided for diagnostics and/or follow-up of a Treponema infection, said carrier comprising at least one immobilized cardiolipin and at least...

20060171968 - Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine: The present invention relates to a method of preventive treatment of allergy to an allergen in a subject comprising a) administering an allergy vaccine containing the allergen as active substance to the subject via an oromucosal route, b) wherein the subject to be treated is unsensitised in the sense of...

20060171969 - Oral pharmaceutical forms of liquid drugs having improved bioavailability: The present invention relates to new pharmaceutical compositions for the administration of liquid drugs in solid oral forms, said compositions comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier....

20060171970 - Pharmaceutical formulation delivery system: The invention relates to the development of a simple and inexpensive oral delivery system for customized pharmaceutical formulations for treating patients having conditions such as HIV/AIDS, cancer, and heart disease. The system includes a) a plurality of prepackaged pharmaceutical formulations containing at least two pharmacologically active ingredients in periodic (e.g.,...

20060171972 - Coated/treated metal silicate absorbent particles: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care...

20060171971 - Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making: An oil-in-water emulsion composition for wet-wipes delivering a particulate skin health benefit ingredient in the oil phase. A process for making an oil-in-water emulsion composition in which the oil phase is first made as a concentrate and then diluted in water....

20060171974 - Compounds, formulations, and methods for treating or preventing rosacea:

20060171973 - Personal care compositions comprising coated/treated metal silicate absorbent particles: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care...

20060171978 - Disinfecting and antimicrobial compositions: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other...

20060171979 - Fungicide mixture formulations: There is provided a fungicidal concentrate comprising azoxystrobin and propiconazole, wherein the concentrate is a suspoemulsion having an aqueous phase, an oil phase and particles dispersed in the aqueous and/or oil phase. Also provided is a method of using the compositions for combating and/or preventing fungal diseases in crops of...

20060171977 - Methods for the identification of fungicidally active compounds based on thymidylate kinase: The invention is related to a method for the identification of fungicides, the use of thymidylate kinases for the identification of fungicides, the use of thymidylate kinase inhibitors as fungicides and methods for combating plant pathogenic fungi....

20060171976 - Mold resistant gypsum wallboard: Mold resistant wallboards and methods of making mold resistant wallboards are provided. Illustrative wallboards have a first antimicrobial composition in the core and a second antimicrobial composition in the facing....

20060171975 - Permeable packaging for liquid interactive preservatives or pesticides: A sealed tube filled and sized to achieve desired application rates for a given wood preservative to be applied internally to wooden structures. Tubing shall be composed as to permit osmotic activation and distribution into target site....

20060171982 - Deforming surface of drug eluting coating to alter drug release profile of a medical device: A method is provided for altering a drug release profile of a coating of a medical device. The method includes determining the drug release profile of the coating of the medical device; determining an increased surface area necessary to alter the drug release profile to an altered drug release profile;...

20060171980 - Implantable or insertable medical devices having optimal surface energy: An implantable or insertable medical device is provided that contains at least one polymeric region which comes into contact with a subject upon implantation or insertion of the device into the subject. The polymeric region(s) contain at least one bulk polymer moiety and at least one surface-active polymer moiety that...

20060171981 - Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes the following: (a) one or more unsaturated hydrocarbon...

20060171983 - Use of vitamin d receptor activators or vitamin d analogs to treat cardiovascular disease: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease among other conditions. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor...

20060171986 - Antibiotic coating of implants: An antibiotic coating of implants is described, which is characterized in that the coating comprises at least one saturated, organic, hydrophobic, low molecular matrix former whose melting point is in the temperature range of 45° C. to 100° C., in which a low molecular, hydrophobic additive is dissolved and that...

20060171984 - Device having hydration inhibitor: Medical devices comprising an interventional component for delivering multiple beneficial agents in which a hydration inhibitor controls release of at least one beneficial agent from the device. The hydration inhibitor is relatively less hydrophilic than the beneficial agent and preferably is a drug. Suitable beneficial agents include (I) dexamethasone, estradiol,...

20060171985 - Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility: The present invention relates to phase separated polymeric regions and to their use in conjunction with implantable or insertable medical devices. In some aspects of the invention, phase separated polymeric regions are provided that include (a) at least one biostable polymeric phase and (b) at least one biodisintegrable polymeric phase,...

20060171989 - Control of drug release by transient modification of local microenvironments: Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an implantable drug delivery device, which method comprises the step of providing a release-modifying agent within or proximate to the...

20060171990 - Drug delivery materials made by sol/gel technology: The present invention relates to a method of producing a drug delivery material by encapsulating a biologically or therapeutically active agent in a shell, combining the encapsulated agent with a sol, and converting the combination into a solid or semi-solid drug delivery material. The present invention further relates to drug...

20060171988 - Method of treatment using foams as artificial lymph nodes: The present invention relates to pharmaceutical compositions for the improved activation of cells of the immune system that comprise a biocompatible implantable and an active pharmaceutical ingredient to be integrated into said foam, wherein said composition specifically activates cells of the immune system. In one preferred embodiment, said active pharmaceutical...

20060171987 - Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix: Using ethanol as plasticizer for preparing subcutaneous implants containing a dispersed active principle in a PLGA-based matrix by means of extrusion, the extrusion temperature, generally higher than 75° C., can be reduced to temperatures higher than the Tg of the PLGA, but lower than the boiling point of ethanol and...

20060171991 - Method for stromal corneal repair and refractive alteration: A method and means of providing stromal repair and improved refractive correction by creating corneal stromal collagen tissue with fibril diameter and spacing that duplicates the optical transmission and diffusion characteristics of natural corneal collagen. The repair method includes implanting the collagen scaffold during laser corneal ablation or other interlamellar...

20060171992 - Blood glucose regulating composition: The invention provides the use of a whey protein hydrolysate in an edible composition the whey protein hydrolysate being able to induce the cellular release of glucagon-like-peptides and cholecystokinins and/or increasing glucose uptake in target tissues, wherein the whey protein hydrolysate regulates blood glucose levels or results in, or is...

20060171993 - Method of improving antioxidant status of an infant: The present invention relates generally to a method of improving the antioxidant status of an infant. More particularly, the present invention relates to a method of improving the antioxidant status of an infant by administering a mixture of natural tocopherols. The natural tocopherol mixture is an effective blend of α-...

20060171994 - Medicinal table with prolonged release of the active principle: The invention concerns a medicinal tablet to be sucked made with boiled sugar of solid consistency designed to dissolve in the buccal cavity, comprising at least an active principle. The invention is characterised in that it further comprises at least a matrix agent for slowing down the release of the...

20060171995 - Formulation for increasing the deposition of dietary carotenoids in eggs: The absorption and deposition of carotenoids added to poultry diets into the yolk of eggs produced by the poultry is improved by adding a carotenoid formulation comprising a carotenoid, a vegetable oil, a surfactant, a chelating agent, an antioxidant, an alkali and a solvent. The carotenoid formulation can reduce the...

20060171996 - Antibacterial pectocellulose: Antibacterial pectocellulosic fibers or antibacterial pectocellulosic fiber fabrics obtained by treating pectocellulosic fibers or pectocellulosic fabrics with at least one chemical substance selected from the group consisting of acids, bases, salts thereof, chelating agents, and a pectin-degrading enzyme to lower the pectin content in pectocellulosic fibers to 1 to 80%...

20060171998 - Sanitary wipes and seat covers for gym equipment: Wipes: Large in size to clean gym equipment disinfectant and sanitizes equipment disposable Seat Covers: Large and small in size to accommodate gym equipment Protects from perspiration Velcro for easy detaching disposable...

20060171997 - Self-inflating article: The self-inflating article of the present invention contains a self-inflating personal care article contains, an inflatable bladder containing a substrate, at least one rupturable reservoir, a cleansing composition wherein said rupturable reservoir is positioned within the sack of the inflatable bladder. The self-inflating article surprisingly provides effective cleansing benefits to...

20060171999 - Textiles with chitosan core-shell particles: The present invention describes a novel antibacterial treatment on textile materials using polymeric core-shell particles dispersing in water. These particles are prepared from a surfactant-free emulsion polymerization according to the method of U.S. Pat. No. 6,573,313 and have average particle sizes in the range of 100 to 1000 nm in...

20060172000 - Compositions for wound treatment: A wound dressing composition comprising a chitosan and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds....

20060172001 - Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing...

20060172002 - Patch containing nonsteroidal antinflammatory and analgesic agent: An adhesive patch containing a non-steroidal anti-inflammatory agent, comprising a support and an adhesive layer laminated on this support, wherein the adhesive layer contains a non-steroidal anti-inflammatory agent having a carboxyl group or its salt, and polyethylene glycol having an average molecular weight of 1000 or more....

20060172003 - Modular targeted liposomal delivery system: A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing...

20060172004 - Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin: The present invention discloses oral compositions comprising pentagastrin (PG) as an effective diagnostic agent for gastric acid secretion. The composition further comprises one or more agents that preserve the availability of PG in the gastric fluids, so that the biological activity of PG is maintained. The pharmaceutical compositions according to...

20060172005 - Tablet and process for producing the same: An object of the present invention relates to a tablet which comprises an active ingredient and a cyclodextrin or a cyclodextrin derivative and rapidly disintegrates in the oral cavity, etc. The present invention provides a tablet in which 70% by mass or more of the components of the tablet is...

20060172006 - Sustained-release tramadol formulations with 24-hour clinical efficacy: There is disclosed a once daily oral pharmaceutical compositon for controlled release of tramadol or a salt thereof, wherein the composition, when ingested orally, provides a clinical effect over 24 hours which is a least as good as the clinical effect over 24 hours of two doses of a twice...

20060172007 - Compositions and methods for reducing vaginal ph: This invention relates to aqueous buffered compositions and methods for lowering vaginal pH and reducing the level of self-perceived vaginal odor. Such compositions may be applied to the vaginal area to lower vaginal pH and assist in maintaining such pH over a period of time....

20060172008 - Freeze-dried fibrin matrices and methods for preparation thereof: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified...

20060172011 - Medical treatment: Provided is a particle capable of being inserted into or taken up by a cell comprising i) a polynucleotide coding for a modulator of Notch signalling; and ii) a polynucleotide coding for an antigen or antigenic determinant thereof. Methods for using the particles are also described....

20060172010 - Process for preparing particles containing an antiviral: A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein...

20060172009 - The formulation and presentation of medicaments: A medicament package (10,30) comprises a vessel (12,32) adapted to hold a quantity of a liquid vehicle. The vessel (12,32) has an opening formed therein, to which opening is bonded a deformable enclosure (18,38). A medicament container (20) that contains a unit dose of a medicament is received within the...

20060172012 - Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks: Disclosed are improvements in human nutrition involving a unique combination of natural products constituting anti-inflammatory compositions which can reduce cardiovascular disease risks as well as play a positive role in other conditions and diseases for which key indicators, especially selected from the group consisting of C-reactive protein (CRP) levels, cyclooxygenase-2...

20060172013 - Process for preparing copper oxide-coated antibacterial material: Disclosed herein is an antibacterial material exhibiting constant, stable, and potent antibacterial, bactericidal and antifungal effects by formation of uniform, hard and thin film-like copper oxide coatings on surfaces of inoxidizable natural materials including mineral materials such as ceramics, glass, stone, tile, pumice and sand, to which a plating method...

20060172015 - Methods and pharmaceutical compositions for inhibiting metastasis of malignant tumors and growth of leukemic cells: The present invention provides methods for inhibiting metastasis of malignant tumors and growth of leukemic cells, which comprise administering a pharmaceutically effective amount of nano-gold. The present invention also provides pharmaceutical compositions, which comprise a pharmaceutically effective amount of nano-gold and are useful in inhibiting metastasis of malignant tumors and...

20060172014 - Treatment of lung cancer with active vitamin d compounds in combination with other treatments: The present invention relates to a method for treating or ameliorating lung cancer in an animal by administering to the animal active vitamin D compounds or mimics thereof by high dose pulse administration in combination with one or more chemotherapeutic agents or radiotherapeutic agents/treatments....

20060172016 - Muscle cramp reliever: A novel beverage composition, which comprises a mixture of water, natural flavorings and color, and a very specific concentration of salts(s), which when administered orally to a person with a muscle spasm, commonly known as a cramp, stops the muscle cramp within a very short period of time, and which...

20060172017 - Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces: Apparatus and methods deliver vasoconstrictive agents simultaneously with capnic gases. The capnic gases can enhance the effectiveness of the vasoconstrictive agent, lower the dosage of drug or concentration of agent necessary to achieve a therapeutic result, or both. Exemplary capnic gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute...

20060172018 - Nitric oxide delivery system: Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation...

20060172019 - Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders: The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and/or activity of osteoclasts), and/or...

20060172020 - Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties: Provided is an herbal extract-based composition comprising an extract of Gynostemma pentaphyllum, an extract of Crataegus pinnatifidia (hawthorn), an extract of Camellia sinensis (green tea), and an extract of Momordica charantia (bitter melon). The composition may further comprise an extract of mulberry (Morus species). Also provided is a process for...

20060172021 - Herbal compositions for the prevention or treatment of symptoms of stress and infection: The present invention provides herbal compositions useful for the prevention or treatment of the symptoms of stress and/or infection in a subject in need thereof. The herb-containing compositions of the invention can be formulated in a dry delivery system, liquid delivery system, or a controlled-release vehicle. The herb-containing compositions of...

20060172022 - Skin treating salve composition: A salve composition and method for topically treating a variety of deleterious skin conditions and for maintaining the wellness of skin comprises, as active ingredients, 100% pure hydrogenated vegetable oil and cocoa butter and a variety of enhancers, such as olive oil, jojoba oil and primrose oil. The basic composition...

20060172023 - Use of pinolenic acid: Method of managing weight by administering a composition including pinolenic acid or derivative such as a glyceride thereof. The composition may be pine nut oil or a derivative thereof and may be used as a food supplement or food product such as margarine or as a pharmaceutical composition, e.g. in...